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1. INTRODUCTION 
Oral route is most popular for systemic effect due to its easy of 
ingestion, pain avoidance, versatility and most importantly patient 
compliance. Solid oral delivery systems (especially tablets) is system of 
choice among all drug delivery system and they do not require special 
treatment and are therefore less expensive to manufacture, likewise 
immediate release tablets are more acceptable among all the tablets. 
Based on their drug-release characteristics, tablets can be classified 
into three types, immediate release, extended release and delayed 
release. For immediate release tablets the drug is intended to be 
released rapidly after administration, or the tablet is dissolved and 
administered as a solution. This is the most common type of tablet 
and includes disintegrating, chewable, effervescent, sublingual and 
buccal tablets. They design to disintegrate and release their 
medication with no special rate controlling features. Immediate 
Release Tablets are those tablets which are designed to disintegrate 
and release their medication with no special rate controlling features, 
such as special coatings and other techniques. In pharmaceutical 
industries, manufactures of generic tablets are usually focused on the 
optimization of the excipients mixture composition to obtain a product 
that meet established standard1.  
An ideal dosage regimen in the drug therapy of any disease or 
the goal of any drug delivery system is the one, which immediately 
attains the desired therapeutic concentration of drug in plasma (or at 
the site of action) and maintains it constant for the entire duration 
treatment. 
Pharmaceutical products designed for oral delivery and 
currently available on the prescription and over-the-counter markets 
are mostly the immediate release type, which are designed for 
immediate release of drug for rapid absorption. Immediate release 
drug delivery systems are designed to provide immediate drug levels in 
short period of time. In recent decades, a variety of pharmaceutical 
research has been conducted to develop new dosage forms considering 
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quality of life, most of these efforts have been focused on ease of 
medication. 
At present novel drug delivery systems are developed for 
expanding  markets/indications,  extending  product  life cycles and 
generating opportunities. Oral administration is the most popular 
route for systemic effects due to its ease of ingestion, pain, avoidance, 
versatility and most importantly patient compliance. In these solid 
formulations do not require sterile   conditions   and   are   therefore,   
less   expensive   to manufacture32. 
An immediate release dosage form allows a manufacturer to 
extend market exclusivity, while offering patients a convenient dosage 
form or dosage regimen. Recently immediate release tablets have 
started gaining popularity and acceptance as a drug delivery system, 
mainly because they are easy to administer, has quick onset of action 
is economical and lead to better patientcompliance. They are also a 
tool for expanding markets, extending product life cycles and 
generating opportunities. Superdisintegrants are first choice of 
excipients which are extensively used for the formulation development 
of the immediate release tablets as they effectively result into the 
immediate disintegration, release and absorption of the drug after 
administration into the body. 
 
1.1 Introduction to Solid Oral Dosage Forms: 
Tablet is the most popular among all dosage forms existing 
today because of its convenience of self-administration, compactness 
and easy manufacturing; Sometimes immediate onset of action is 
required than conventional therapy in many cases. Tablets are the 
most popular dosage form because of its unique properties such as 
ease of administration, low cost and non-invasive therapy 
etc.Therapeutic success of any therapy depends on the patient’s 
compliance toward the therapy. As a drug entity nears the end of its 
patent life, it is common for pharmaceutical manufacturers to develop 
a given drug entity in a new and improved dosage form.   
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A tablet is a pharmaceutical dosage form. It comprises a 
mixture of active substances and excipients, usually in powder form, 
pressed or compacted from a powder into a solid dose. The excipients 
can include diluents, binders or granulating agents, glidants (flow 
aids) and lubricants to ensure efficient tableting, disintegrants to 
promote tablet break-up in the digestive tract; sweeteners or flavors to 
enhance taste, and pigments to make the tablets visually attractive. 
Apolymer coating is often applied to make the tablet smoother and 
easier to swallow, to control the release rate of the active ingredient, to 
make it more resistant to the environment (extending its shelf life), or 
to enhance the tablet's appearance. 
 
 The compressed tablet is the most popular dosage form in use 
today. About two-thirds of all prescriptions are dispensed as solid 
dosage forms, and half of these are compressed tablets. A tablet can 
be formulated to deliver an accurate dosage to a specific site; it is 
usually taken orally, but can be administered sublingually, buccally, 
rectally or intra vaginally. The tablet is just one of the many forms 
that an oral drug can take such as syrups, elixirs, suspensions, and 
emulsions. Medicinal tablets were originally made in the shape of a 
disk of whatever color their components determined, but are now 
made in many shapes and colors to help distinguish different 
medicines. Tablets are often stamped with symbols, letters, and 
numbers, which enable them to be identified. Sizes of tablets to be 
swallowed range from a few millimeters to about a centimeter. 
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1.2. Types and Classes of Tablet: 4,5 
A. Oral Tablets for Ingestion: 
1. Compressed tablets 
2. Multiple compressed tablets 
3. Layered tablets 
4. Compression-coated tablets 
5. Repeat-action tablets 
6. Delayed-action and enteric-coated tablets 
7. Sugar and chocolate-coated tablets 
8. Film coated tablets 
9. Chewable tablets  
B. Tablets Used in the Oral Cavity: 4,5 
1. Buccal tablets 
2. Sublingual tablets 
3. Troches and lozenges 
4. Dental cones 
C. Tablets Administered by Other Routes: 4,5 
1. Implantation tablets 
2. Vaginal tablets 
D. Tablets Used to Prepare Solutions: 4,5 
1. Effervescent tablets 
2. Dispensing tablets 
3. Hypodermic tablets 
4. Tablet triturates 
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1.3 Introduction to Immediate Release Tablets:6 
Definition: Immediate release tablets are those which disintegrate 
rapidly and get dissolved to release the medicaments. The term 
“release” includes the provision (or presentation) of drug from the 
formulation to the gastrointestinal tract, to body tissues and/or into 
systemic circulation. In the present case, immediate release may be 
provided for by way of an appropriate pharmaceutically acceptable 
diluents or carrier, which diluents or carrier does not prolong, to an 
appreciable extent, the rate of drug release and/or absorption. It also 
finds applications in the field of local delivery of drug to the stomach 
and proximal small intestine and importantly in treating 
microorganisms (Helicobacter pylori).  
In immediate release tablets, disintegration is one of the 
important parameter. With the help of design of experiment (DOE) 
approach, process variables are first ‘screened’ to determine which are 
important to the outcome (excipients type, percentage, disintegration 
time (DT), etc. Next step is the ‘optimization’, when the best settings 
for the important variables are determined. It involves the use of 
‘mixture designs’ for changing mixture composition and exploring how 
such changes will affect the properties of the mixture. Immediate 
release tablets have gained prominence of being new drug delivery 
systems. Most immediate release tablets are intended to disintegrate 
in the stomach, where the pH is acidic. 
Immediate release drug delivery system are based on single or 
multiple-unit reservoir or matrix system, which are designed to  
provide immediate drug  levels  in  short  period of  time. 
Immediate release drug delivery is desirable for drugs having 
long biological half life, high bioavailability, lower clearance and lower 
elimination half life. But main criterion for immediate release dosage 
form is poor solubility of the drug and  need  the  immediate action of  
drug  to  treat  unwanted defect or disease30.  
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Immediate release solid oral dosage forms are classified as 
either  having  rapid  or  slow  dissolution  rates.  Immediate release 
dosage forms are those for which ≥85% of labelled amount  dissolves  
within  30  min.  For  immediate  release tablets, the only barrier to 
drug release is simple disintegration or erosion stage, which is 
generally accomplished in less than one hour. To enhance dissolution 
and hence bioavailability of any drug from immediate release tablets, 
disintegration is one of   the   important   process.   Few   Super-
disintegrants   are available commercially as Croscarmellose sodium, 
Crospovidone and SSG31. 
 
1.4.DESIRED CRITERIA FOR IMMEDIATE RELEASE DRUG 
DELIVERY SYSTEM: 
1.4.1. Ideal Properties5 
Immediate release dosage form should 
1. It should dissolve or disintegrate in the stomach within a short 
period In the case of solid dosage.  
2. Should show first absorption and dissolution of drug.  
3. Rapid onset of action always seen with immediate release tablets.  
4. Must be compatible with taste masking.  
5. Be portable without fragility concern.  
6. It should not leave minimal or no residue in the mouth after oral 
administration.  
7. Provides pleasing mouth feel.  
8. Exhibit low sensitivity to environmental condition as humidity and 
temperature.  
9. Be manufactured using conventional processing and packaging 
equipment at low cost.  
1.4.2.Advantages2,3 
An immediate release pharmaceutical preparation offers 
1. Improved stability, bioavailability.  
2. Decreased disintegration and dissolution times for immediate 
release oral dosage forms.  
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3. Suitable for controlled, sustained release actives.  
4. High drug loading is possible.  
5. Ability to provide advantages of liquid medication in the form of 
solid preparation.  
6. Adaptable and amenable to existing processing and packaging 
machinery.  
7. Cost- effective.  
8. Improved compliance added convenience. 
9. Accurate dose: The immediate/fast dissolve dosage forms have the 
added advantages of convenience and accurate dosing as 
compared to liquids.  
10. Ease of swallowing is possible. 
11. Bilayer tablet is possible for sequential release of two drugs in 
combination and separate two incompatible substance. 
 
1.4.3.Disadvantage[2][3] 
1. Possess swallowing difficulty.  
2. Onset of action is slow and depends on disintegration and 
dissolution. Some drugs resist compression, due to their 
amorphous nature or low-density 
3. Drugs having bitter taste, objectionable odor or drugs that are 
sensitive to oxygen may require encapsulation or coating of tablet. 
4. Drug release at a time may produce high plasma concentration 
which may produce toxicity. 
5. Frequent dosing is necessary for drug with short half-life.  
 
1.4.4.Salient Features 
• Drugs should possessing long biological half-life for immediate 
release drug delivery. 
• The drug is released quickly and completely in one shot.  
• High bioavailability expected with immediate release dosage 
form.  
• Lower clearance and lower elimination half-life are also 
requirement for immediate release drug delivery system. 
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• But main criterion for immediate release dosage form is poor 
solubility of the drug and need the immediate action of drug to 
treat unwanted defect or disease.  
• Rapid drug therapy intervention is possible.  
• New business opportunities like product differentiation, line 
extension and lifecycle management, exclusively of product 
promotion. 
1.5.Criteria for Drug Selection 
• Poor solubility of the drug and need immediate drug action in 
case of immediate release dosage form. 
• The immediate release compositions comprise micronized drug 
in an amount sufficient to provide the desired daily dosage, that 
is, an amount of about 10 mg to about 1000 mg, more 
preferably an amount of about 20 mg to 400 mg. 
• Immediate release compositions from which about 50% of the 
micronized drug is dissolved in vitro within about 15 minutes, 
more preferably at least about 80% of the drug is dissolved in 
vitro within about 30 minutes. 
• Carrier materials for immediate release compositions preferably 
are selected to provide a disintegration time less than about 30 
minutes, preferably about 20 minutes or less, more preferably 
about 18 minutes or less. 
1.6.Unsuitable drug characteristic for immediate release tablets: 
• Drug are not suitable for immediate release tablets which 
having short biological half-life. 
• Drug with low bioavailability are also not desirable candidate for 
immediate release tablets. 
• Drug with higher clearance and higher elimination half-life 
are also not desirable candidate for immediate release 
tablets. 
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1.7.Pharmacokinetics:[6] 
In this consideration, study has done on absorption, 
distribution, metabolism and excretion. After absorption, drug attains 
therapeutic level and therefore elicits pharmacological effect, so 
bothrate and extend of absorption is important. In conventional 
dosage form there is delay in disintegration and therefore dissolution 
is fast. Drug distribution depends on many factors like tissue 
permeability, perfusion rate, binding of drug to tissue, disease state, 
drug interaction etc. Duration and intensity of action depends upon 
rate of drug removal from the body or site of action i.e. 
biotransformation. Decrease in liver volume, regional blood flow to 
liver reduces thebiotransformation of drug through oxidation, 
reduction and hydrolysis. Excretion by renal clearance is slowed, thus 
half-life of renal excreted drugs increase.  
 
1.8.Pharmacodynamics:[6]    
Drug reception interaction impaired in elderly as well as in 
young adult due to undue development of organ. 
1. Decreased ability of the body to respond reflexive stimuli, 
cardiac output, and orthostatic hypotension may see in taking 
antihypertensive like prazosin. Immunity is less and taken into 
consideration while administered antibiotics 
2. Altered response to drug therapy-elderly show diminished 
bronchodilator effect of theophylline shows increased sensitivity 
to barbiturates 
3. Concomitant illnesses are often present in elderly, which is also 
taken into consideration, while multiple drug therapy 
prescribed. 
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1.9.Technology for Immediate release Tablets[6] 
Conventional Techniques 
Conventional technique used in the preparation of immediate release 
tablets 
✓ Tablet molding technique  
✓ Direct compression technique  
✓ Granulation technique  
✓ Mass extrusion technique 
Several Technologies are available to manufacture immediate release 
tablets. The most common preparation methods are molding, 
lyophilisation or freeze drying, direct compression, spray drying and 
sublimation. 
A. Tablet molding technique[4] [6] 
Water-soluble ingredients are used in tablet molding technique 
which facilitate tablet to disintegrate and dissolve rapidly. A hydro 
alcoholic solvent use to moisten powder blend and is molded in to 
tablet using compression pressure lower than used in conventional 
tablets compression. The solvent is then removed by air-drying. Two 
problems commonly encountered are mechanical strength and poor 
taste masking characteristics in this technique. 
B. Direct compression technique[4] [6] 
The term “direct compression” is defined as the process by 
which tablets are compressed directly from powder mixture of API and 
suitable excipients. No pre-treatment of the powder blend by wet or 
dry granulation procedure is required. Amongst the techniques used 
to prepare tablets, direct compression is the most advanced 
technology. It involves only blending and compression, thus offering 
advantage particularly in terms of speedy production, as it requires 
fewer unit operations, less machinery, reduced number of personnel 
and considerably less processing time along with increased product 
stability. 
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Advantages[6] 
1. Direct compression is more efficient and economical process as 
compared to other processes, because it involves only dry 
blending and compaction of API and necessary excipients. 
2. The most important advantage of direct compression is that it is 
an economical process. Reduced processing time, reduced labor 
costs, fewer manufacturing steps, and less number of 
equipment’s is required, less process validation, reduced 
consumption of power. 
3. Elimination of heat and moisture, thus increasing not only the 
stability but also the suitability of the process for thermolabile 
and moisture sensitive API. 
4. Particle size uniformity. 
5. Prime particle dissolution. 
In case of directly compressed tablets after disintegration each 
primary drug particle is liberated. While in the case of tablets 
prepared by compression of granules small drug particles with a 
larger surface area adhere together into larger agglomerates, thus 
decreasing the surface area available for dissolution. 
Disadvantages 
a) Excipients Related[6] 
1. Problems in the uniform distribution of low dose drugs. 
2. High dose drugs having high bulk volume, poor compressibility 
and poor flow ability are not suitable for direct compression for 
example, Aluminum Hydroxide, Magnesium Hydroxide. 
3. The choice of excipients for direct compression is extremely 
critical. Direct compression diluents and binders must possess 
both good compressibility and good flow ability. 
4. Many active ingredients are not compressible either in 
crystalline or amorphous forms. 
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b) PROCESS Related [7] 
1. Capping, lamination, splitting, or layering of tablets is 
sometimes related to air entrapment during direct compression. 
When air is trapped the resulting tablets expand when the 
pressure of tablet is released, resulting in splits or layers in the 
tablet. 
2. In some case it requires greater sophistication in blending and 
compression equipment’s. 
 
C. Granulation technique[4] 
Granulation may be defined as a size enlargement process 
which converts small particles into physically stronger &larger 
agglomerates. The objective of granulation is to improve powder flow 
and handling, decrease dustiness, and prevent segregation of the 
constituents. 
 
Granulation method can be broadly classified into two types 
(i) Wet granulation[4] 
(ii) Dry granulation[4] 
Ideal characteristics of granules 
The ideal characteristics of granules include spherical shape, 
smaller particle size distribution with sufficient fines to fill void spaces 
between granules, adequate moisture (between 1-2%), good flow, good 
compressibility and sufficient hardness etc. 
The effectiveness of granulation depends on the following 
properties: 
• Particle size of the drug and excipients 
• Type of binder (strong or weak) 
• Volume of binder (less or more) 
• Wet massing time (less or more) 
• Amount of shear applied 
• Drying rate (Hydrate formation and polymorphism) 
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(i) Wet granulation[4] 
Wet granulation is a commonly used unit operation in the 
pharmaceutical industry. Wet granulation is often carried out utilizing 
a high-shear mixer. The high-shear granulation process is a rapid 
process which is susceptible for over-wetting. Thus, the liquid amount 
added is critical and the optimal amount is affected by the properties 
of the raw materials. Power consumption of the impeller motor and 
the impeller torque have been applied to monitor the rheological 
properties of the wet mass during agglomeration and, thereby, have 
been used to determine the end-point of water addition. However, 
these methods are affected by the equipment variables. 
Important steps involved in wet granulation 
• Mixing of drug(s) and excipients. 
• Preparation of binder solution. 
• Mixing of binder solution with powder mixture to form wet 
mass. 
• Course screening of wet mass using a suitable sieve (6-12 
screens). 
• Drying of moist granules. 
• Screening of dry granules through a suitable sieve (14-20 
screen). 
• Mixing of screened granules with disintegrant, glidant, and 
lubricant.(Manish  
Limitation of wet granulation[4] 
• The greatest disadvantage of wet granulation is its cost. It is an 
expensive process because of labor, time, equipment, energy 
and space requirements. 
• Loss of material during various stages of processing. 
• Stability may be a major concern for moisture sensitive or 
thermolabile drugs. 
• An inherent limitation of wet granulation is that any 
incompatibility between formulation components is aggravated. 
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1.10.Special wet granulation techniques 
▪ High shear mixture granulation 
▪ Fluid bed granulation 
▪ Extrusion-spheronization 
▪ Spray drying 
 
(ii) Dry granulation[4] 
In dry granulation process the powder mixture is compressed 
without the use of heat and solvent. The two basic procedures are to 
form a compact of material by compression and then to mill the 
compact to obtain granules. 
Two methods are used for dry granulation.The more widely used 
method is slugging, where the powder is precompressed and the 
resulting tablets or slugs are milled to yield granules.The other 
method is to precompress the powder with pressure rolls using a 
machine such as Chilosonator. 
Advantages 
The main advantages of dry granulation or slugging are that it 
uses less equipment’s and space. It eliminates the need for binder 
solution, heavy mixing equipment and the costly and time consuming 
drying step required for wet granulation. 
Slugging can be used for advantages in the following situations 
▪ For moisture sensitive material 
▪ For heat sensitive material 
▪ For improved disintegration since powder particles are not 
bonded together by a binder. 
Disadvantages 
• It requires a specialized heavy duty tablet press to form slug. 
• It does not permit uniform color distribution as can be achieved 
with wet granulation where the dye can be incorporated into 
binder liquid. 
• The process tends to create more dust than wet granulation, 
increasing the potential contamination. 
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Steps in dry granulation 
1. Milling of drugs and excipients 
2. Mixing of milled powders 
3. Compression into large, hard tablets to make slug 
4. Screening of slugs 
5. Mixing with lubricant and disintegrating agent 
6. Tablet compression 
Two main dry granulation processes 
a) Slugging process 
Granulation by slugging is the process of compressing dry 
powder of tablet formulation with tablet press having die cavity large 
enough in diameter to fill quickly. The accuracy or condition of slug is 
not too important. Only sufficient pressure to compact the powder 
into uniform slugs should be used. Once slugs are produced they are 
reduced to appropriate granule size for final compression by screening 
and milling. 
b) Roller compaction 
The compaction of powder by means of pressure roll can also be 
accomplished by a machine called Chilosonator. Unlike tablet 
machine, the Chilosonator turns out a compacted mass in a steady 
continuous flow. The powder is fed down between the rollers from the 
hopper to feed the powder into the compaction zone. Like slugs, the 
aggregates are screened or milled for production into granules. 
 
D. Mass-Extrusion technique 
Here softening of active blend done with solvent mixture of 
water-soluble polyethylene glycol and methanol and subsequent 
expulsion of softened mass through the extruder or syringe to get a 
cylinder of the product into even segments using heated blade to form 
tablets. In case of bitter drug granules can be coated with the help of 
dried cylinder to achieve taste masking. 
 
 
Solid dispersions method: 
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The immediate release dosage forms containing a solid 
dispersion that enhances the Solubility of a “low-solubility drug,” 
meaning that the drug may be either “substantially Water-insoluble,” 
which means that the drug has a minimum aqueous solubility at 
physiologically relevant pH (e.g., pH 1-8) of less than 0.01 mg/mL, 
“sparingly water-soluble,” that is, has an aqueous solubility up to 
about 1to2 mg/mL, or even low to moderate aqueous- solubility, 
having an aqueous-solubility from about 1 mg/mL to as high as about 
20 to 40 mg/ml. 
 
1.11.Few therapeutical area uses in the formulation of immediate 
release dosage form33:  
 
1. Analgesics and Anti-inflammatory Agents: Ibuprofen, 
Indomethacin, Ketoprofen, Meclofenamic Acid, Mefenamicacid, 
Nabumetone, Oxyphenbutazone. 
2. Anthelmintics: Albendazole, Mebendazole, Oxantel, Embonate, 
Embonate, Thiabendazole. 
3. Anti-Arrhythmic Agents: Amiodarone Hcl, Disopyramide. 
4. Anti-bacterial Agents: Penicillin, Ciprofloxacin HCl, 
Clarithromycin, Clofazimine, Doxycycline, Erythromycin, Nalidixic 
Acid, Nitrofurantoin, Rifampicin, Sulphabenzamide, 
Sulphamethoxazole, Sulphapyridine, Trimethoprim.  
5. Anti-coagulants: Dicoumarol, Dipyridamole. 
6. Anti-depressants: Amoxapine, Ciclazindol, Maprotiline HCl, 
Mianserin HCl,Trazodone HCl. 
7. Histamine H,-Receptor Antagonists: cyclizine, cyproheptadine 
HCl, dimenhydrinate, flunarizine HCl. 
8. Anti-diabetics: Acetohexamide, Chlorpropamide, Glibenclamide, 
Gliclazide, Glipizide. 
9. Anti-hypertensive Agents: Amlodipine, Carvedilol, Benidipine, 
Darodipine, Dilitazem HCl, Diazoxide, Guanabenz Acetate, 
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Indoramin, Isradipine, Minoxidil, Nicardipine HCl, Nifedipine, 
Nimodipine, Reserpine.  
10. Gastro-intestinal Agents: cimetidine, cisapride, diphenoxylate 
HCl,famotidine, loperamide, mesalazine, nizatidine, omeprazole.  
11. Diuretics: Acetazolamide, amiloride, bendrofluazide, bumetanide, 
chlorothiazide, chlorthalidone, ethacrynic acid, frusemide, 
metolazone, spironolactone, triamterene.  
12. Cardiac Inotropic Agents: Amrinone, Digitoxin, Digoxin, 
Enoximone, Lanatoside C, Medigoxin.  
13. Anxiolytic, Sedatives, Hypnotics and Neuroleptics: Etizolam, 
Alprazolam, Amylobarbitone, Barbitone, Bentazepam, 
Bromazepam, Bromperidol, Brotizolam, Chlormethiazole, 
Chlorpromazine, Diazepam, Droperidol.  
14. Histamine H,-Receptor Antagonists: Acrivastine, astemizole, 
cinnarizine, cyclizine, cyproheptadine HCl, dimenhydrinate, 
flunarizine HCl.  
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1.12.DISINTEGRANTS: 
Disintegrants   are   agents   added   to    tablet   and   some 
encapsulated formulations to promote the breakup of the tablet and 
capsule “slugs’ into smaller fragments in an aqueous environment 
there by increasing the available surface area and promoting a more 
rapid release of the drug substance. Superdisintegrants are generally 
used at a low level in the solid dosage form, typically 1- 10 % by 
weight relative to the total weight of the dosage unit. Diverse 
categories of Superdisintegrants such as synthetic, semi-synthetic, 
natural and co-processed blends etc. have been employed to develop 
effective immediate release tablets and to overcome the limitations of 
conventional tablet dosage form.36 
They promote  moisture  penetration  and  dispersion  of  the 
tablet matrix. Tablet disintegration has received considerable 
attention as an essential step in obtaining fast drug release. The 
disintegrants have the major function to oppose the efficiency of the 
tablet binder and the physical forces that act under compression to 
form the tablet. The stronger the binder, the more effective must be 
the disintegrating agents in order for the tablet to release its 
medication. Ideally, it should cause the tablet to disrupt, not only into 
the granules from which it was compressed, but also into powder 
particles from which the granulation was prepared. Most common 
tablets are those intended  to  be  swallowed  whole  and  to  
disintegrate  and release their medicaments rapidly in the 
gastrointestinal tract (GIT). The proper choice of disintegrant and its 
consistency of performance are of critical importance to the 
formulation development of such tablets. In more recent years, 
increasing attention has been paid to formulating not only fast 
dissolving and/or  disintegrating  tablets  that  are  swallowed,  but  
also orally  disintegrating  tablets  that  are  intended  to  dissolve 
and/or disintegrate rapidly in the mouth. Most prior studies have 
focused on the function related properties of superdisintegrants with 
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special emphasis on correlating these functional  properties  to  
disintegrant  efficiency  and  drug release rate.37 
1.13.MECHANISM OF DISINTEGRATION BY 
SUPERDISINTEGRANTS: 
There are five major mechanisms for tablet disintegration as follows:- 
1) Swelling 
2) Porosity and Capillary Action (Wicking) 
3) Deformation 
4) Due to disintegrating particle/particle repulsive forces 
5) Enzymatic reaction 
 
1. Swelling:  
Swelling is believed to be a mechanism in which certain 
disintegrating agents (such as starch) impart the disintegrating 
effect. By swelling in contact with water, the adhesiveness of 
other ingredients in a tablet is overcome causing the tablet to 
fall apart. E.g Sodium starch Glycolate.38 
 
Fig.1. Swelling of granules due to superdisintegrants 
 
 
 
2. Porosity and Capillary Action (Wicking): 
Effective disintegrants that do not swell are believed to 
impart their disintegrating action through porosity and capillary 
action. Tablet porosity provides pathways for the penetration of 
fluid into tablets. The disintegrant particles (with low 
cohesiveness & compressibility) themselves act to enhance 
porosity and provide these pathways into the tablet. Liquid is 
drawn up or “wicked” into these pathways through capillary 
action and rupture the interparticulate bonds causing the tablet 
to break apart. E.g. Crospovidone, Crosscarmillose.39 
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Fig.2. Wicking & Swelling 
 
 
3. Deformation: 
Starch grains are  generally thought to  be “elastic”  in  
nature  meaning  that  grains  that  are  deformed under 
pressure will return to their original shape when that pressure  
is  removed.  But,   with  the  compression  forces involved in 
tableting, these grains are believed to be deformed more 
permanently and are said to be “energy rich” with this energy 
being released upon exposure to water. In other words, the 
ability for starch to swell is higher in “energy rich” starch grains 
than it is for starch grains that have not been deformed under 
pressure.40 
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Fig.3. Deformation and repulsion 
 
 
 
 
 
 
 
 
 
 
 
4. Due  to  disintegrating particle/particle repulsive  forces:  
Another mechanism of disintegration attempts to explain 
the swelling of  tablet  made  with  “nonswellable” disintegrants. 
Guyot-Hermann  has  proposed  a  particle  repulsion  theory 
based on the observation that nonswelling particle also cause 
disintegration of tablets. The electric repulsive forces between 
particles are the  mechanism of disintegration and  water is 
required for it. Researchers found that repulsion is secondary to 
wicking. It is believed that no single mechanism is responsible 
for the action of most disintegrants. But rather, it is more likely 
the result of inter-relationships between these major 
mechanisms. 
5. By Enzymatic Reaction:  
Enzymes present in the body also act  as  disintegrants.  
These  enzymes  enhance  the  binding action of binder and 
helps in disintegration. Due to swelling, pressure is exerted in 
the outer direction that causes the tablet to burst or the 
accelerated absorption of water leads to an enormous increase 
in the volume of granules to promote disintegration.41  
When it comes to immediate-release tablet formulations, 
the choice of disintegrant can have a significant effect on the 
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rate and extent of drug dissolution. Once a tablet disintegrates, 
the characteristics of the API, either alone or assisted by other 
formulation ingredients, determine the  dissolution rate  and 
extent of the API. Thus, the choice of superdisintegrant is 
important, especially with poorly soluble APIs. 
Fig.4. Enzymes enhance helps in disintegration 
 
           
 
 
 
 
 
 
1.14.NOT ALL SUPERDISINTEGRANTS ARE THE SAME: 
The  three  most  common classes  of  superdisintegrants are: 
crospovidone, croscarmellose sodium and sodium starch glycolate. In 
general, all of these provide rapid disintegration at low use levels in 
both wet and dry granulations and direct compression tablet 
processes; however, the classes of disintegrants differ in chemistry 
and particle morphology. Crospovidone possesses unique pyrrolidone 
chemistry and a highly porous particle morphology that results in 
high surface area. The high surface area combined with unique 
chemistry results in high-interfacial activity that serves to enhance 
the dissolution  of  poorly  soluble  drugs  in  a  way  that  is  not 
possible with other disintegrant technologies. Indeed, studies have 
shown that tablets containing a poorly soluble API and crospovidone, 
Type B, have significantly faster dissolution rates compared with 
tablets formulated with other superdisintegrants.  
It has been widely reported that more than 60% of drugs in 
development and over 40% of recently launched drugs have issues 
related to poor solubility, leading to long development times  or  
cancellations.  Before  evaluating  advanced techniques, such as 
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amorphous solid dispersions, more traditional approaches such as the 
influence of superdisintegrants on dissolution are now being 
considered. The selection of a superdisintegrant and the use level 
plays a key role in determining the drug release of finished 
formulations. 
 
1.15.CHOOSING AN OPTIMAL SUPERDISINTEGRANT: 
It is important to consider the impact of the superdisintegrant with 
respect to the performance of the final dosage form. As drug 
dissolution is essential for absorption by the body, formulators no 
longer select disintegrants based on the lowest disintegration time 
because it is important to also consider the effect of the 
superdsintegrant on dissolution. Additionally, the ionic nature of both 
the API and the superdisintegrants must also be considered. Anionic 
superdisintegrants, such as croscarmellose sodium and sodium 
starch glycolate, can interact with cationic APIs and retard 
dissolution. Thus, nonionic superdistegrants are preferred when 
working with cationic APIs. Formulators also consider the impact of 
the superdisintegrant on physical tablet characteristics, such as tablet  
breaking  force  and  friability.  In  today’s  high-speed tablet presses, 
superdisintegrants that provide tablets with high breaking force and 
low friability, while maintaining fast disintegration, are particularly 
important.42  
1.16.SELECTION OF SUPERDISINTEGRANT: 
Since superdisintegrant is used as an excipient in the tablet 
formulation, it has to meet certain criteria other than its swelling 
properties. The requirement placed on the tablet disintegrant should 
be clearly defined. The ideal disintegrants should have 43 
1. Poor solubility 
2. Poor gel formation 
3. Good hydration capacity 
4. Good moulding and flow properties 
5. No tendency to form complexes with the drugs 
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6. Good mouth feel. 
7. It should also be compatible with the other excipients and 
have desirable tableting properties.  
Three  major  groups  of  compounds  have  been  developed 
which swell to many times their original size when placed in water  
while  producing minimal  viscosity effects.  Different commonly used 
superdisintagrants are:44 
 
1. Modified     Starches - Sodium     Carboxymethyl     Starch 
(Chemically   treated   Potato   Starch) i.e.   Sodium   Starch 
Glycolate (Explotab, Primogel). 
Mechanism of  Action: Rapid and  extensive swelling  with 
minimal gelling. 
Effective  Concentration:  4-6%.  Above  8%,  disintegration 
times may actually increase due to gelling and its subsequent 
viscosity producing effects. 
2. Cross-linked  polyvinylpyrrolidone -  water  insoluble  and 
strongly hydrophilic. i.e. crospovidone (Polyplasdone XL, 
Kollidon CL). 
Mechanism of Action: Water wicking, swelling and possibly 
some deformation recovery. 
Effective Concentration:   2-4% 
3. Modified Cellulose - Internally cross-linked form of Sodium 
carboxymethyl      cellulose. i.e.      Ac-Di-Sol      (Accelerates 
Dissolution), Nymcel 
Mechanism of Action: Wicking due to fibrous structure, swelling 
with minimal gelling. 
Effective Concentrations: 1-3% (Direct Compression), 2-4% (Wet 
Granulation) 
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1.17.METHOD OF ADDITION OF SUPERDISINTEGRANTS:  
There are three methods of incorporating disintegrating agents 
into the tablet. 
i) Internal Addition 
In wet granulation method, the disintegrant is added to other 
excipients before wetting  the  powder  with  the  granulating fluid. 
Thereby, the disintegrant is incorporated within the granules. In dry 
granulation method, the disintegrant is added to other excipients 
before compressing the powder between the rollers. In a computer 
optimized experiment, the study show the effect of incorporating a 
disintegrant, croscarmellose sodium, intragranularly, extra granularly 
or distributed equally between the two phases of a tablet in which a 
poorly soluble drug constituted at least 92.5% of the formulation. The 
results analyzed by means of a general quadratic response surface 
model suggest that, tablets with the same total concentration of 
crosscarmellose sodium dissolve at a faster rate when the super 
disintegrant is included intragranularly. Tablet friability is not affected 
by the method of disintegrant incorporation. 
ii) External Addition 
In both wet and dry granulation method, the superdisintegrant 
is added to the granules during dry mixing prior to compression. The 
effect of mode of incorporation of superdisintegrants (croscarmellose 
sodium, sodium starch glycolate and  crospovidone) on dissolution of 
three model drugs with varying aqueous solubility (carbamazepine, 
acetaminophen and cetrizine HCl) from their respective tablet 
formulations by wet granulation was studied. It is proved that 
crospovidone is effective in improving the dissolution of the drugs in 
extra granular mode of addition seems to be the best mode of 
incorporation, irrespective of the solubility of the main tablet component. 
iii) Internal and External  Addition 
In this method, disintegrant is divided into two portions. One 
portion   is   added   before   granule   formation   (intra)   and 
remaining portion is added to granules (extra) with mixing prior to 
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compression. This method can be more effective. If both intragranular 
and extragranular methods are used, extra- granular  portion  break  
the  tablet  into  granules  and  the granules  further  disintegrate  by  
intra-granular  portion  to release the drug substance into solution. 
However, the portion of intra-granular disintegrant (in wet granulation 
processes) is usually not as effective as that of extra-granular due to 
the fact that it is exposed to wetting and drying (as part of the 
granulation process) which reduces the activity of the disintegrant. 
Since a compaction process does not involve its exposure to wetting 
and drying, the intragranular disintegrant tends to retain good 
disintegration activity.44  
 
Table-1 List of Common Disintegrants and Superdisintegrants 
Name of 
excipients 
Category Concentration Stability criteria 
Alginic acid Disintegrants 1-5% 
Hydrolyzes slowly at 
room temperature 
ColloidalSilicon 
Dioxide 
Disintegrants 5-10% 
Hydroscopic , but do 
not liquefy upon 
absorption of water 
Cross- povidone Superdisintegrants 2-5 % 
As hygroscopic in 
nature, stored in an 
air- tight container, in 
a cool and dry place. 
Methyl cellulose Disintegrants 2-10% 
Slightly hygroscopic, 
but stable 
Micro-crystalline 
cellulose 
Superdisintegrants 5-15% 
Stable at dry and air 
tight condition 
Starch Superdisintegrants 5-10% Stable at dry and air 
tight condition  
1.18.ADVANTAGES OF SUPERDISINTEGRANTS:  
The uses of superdisintegrants are extended in the applications 
of immediate release tablets, oral disintegration tablets, fast-
dispersible tablets, capsules, mouth-dissolving films, etc 
• Remarkable  tendency  on   wetting   causing   rapid 
disintegration 
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• No lump formation on disintegration 
• Compatible   with   commonly   used   therapeutical agents and 
excipients 
• Work    equally    effective    in    hydrophilic    and hydrophobic 
formulations. 
• Provides  good  mechanical  strength  to  the  tablet facilitating 
easy packing and transportation. 
• Does not stick to the punches and dyes. 
• Although there are many superdisintegrants, which show superior 
disintegration, the search for newer disintegrants is ongoing and 
researchers are experimenting with modified natural products.45 
1.19.EVALUATION OF TABLETS: 
These tests are as following:- 
1. Appearance  
2. Thickness  
3. Hardness 
4. Weight variation 
5. Friability 
6. Disintegration 
7. Uniformity of dispersion 
8. Wetting Time 
9. Water absorption ratio 
10. Drug content 
11. In vitro Dissolution 
12. Stability studies   
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1.20.CHALLENGES AND LIMITATIONS FOR ODTS: 
Drugs with relatively larger doses, are difficult to formulate into 
ODTs e.g. antibiotics like ciprofloxacin with adult dose tablet 
containing about 500 mg of the drug. 
The application for technologies used for ODTs is limited by the 
amount of drug into each unit dose. The drug dose must be lower 
than 400mg for insoluble drugs and 60mg for soluble drugs. 
However Flashdose technology can accommodate larger drug 
doses and offers improved mechanical strength. Orasolv® technology 
can accommodate a wide range of active pharmaceutical ingredient 
from 1 mg to 500 mg. 
Mechanical strength - ODTs are made of porous or soft molded 
matrices in order to allow its disintegration in mouth. This makes 
tablet friable and handling becomes difficult. 
Orodispersible tablets with highly porous structure and good 
mechanical strength have been developed by sublimation method. 
Also Durasolv®  has much higher mechanical strength  than  Orasolv 
due to the use of higher compaction  pressures during compression. 
Palatability - ODTs are intended to be dissolved in mouth. Most of the 
drugs have bitter taste. Bitter taste can be masked with 
enough sweetener and flavors. Specifically,  methods  of taste masking 
include lipophilic vehicles, coating with polymers, carbohydrates, 
lipids or proteins complexation with cyclodextrins or ion-exchange 
resins, formation of salts, use of salting out layers and solid 
dispersions. OraQuick utilizes its own patented taste masking 
technology i.e. MicroMask®. In MicroMask® technology, taste-
masking process is done by incorporating drug into matrix 
microsphere. 
Drugs in form of ODTs are hygroscopic in nature and hence need to 
be protected from humidity. To overcome humidity problem special 
working facilities can be designed by simple methods and special air-
conditioning systems can be set up. Size of tablet 7 and 8 mm are 
easy to swallow while tablets of size 8mm are easy to handle. Hence, 
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tablet sizes which are both easy to handle and swallow are difficult to 
achieve. For the patient compliance, to make the swallowing easier, 
round shape punches having optimum dimensions can be used. 
Drug candidates should be stable both in water and in saliva, 
should not ionize at oral cavity pH and should be able to permeate 
oral mucosal tissue to diffuse and partition in upper GI epithelium 
(logP > 1, or preferably > 2, not have short half-life). To optimize 
solubility problem of the active pharmaceutical ingredient some solid 
buffers and surfactants can also be chosen. 
ODT requires special packaging for proper stabilization and safety of 
stable product. 
 
1.21.Future of ODTs: 
ODT technology is applicable to a wide range of therapeutic 
agents including generics, thereby adding value, i.e. "supergenerics" 
for veterinary or human application. 
Some new quality control methods can be developed to determine the 
technological aspects of orally disintegrating tablets to define the 
characteristics of ODTs. 
Protein and peptide–based therapeutics that used via oral route, 
have limited bioavailability when administered by immediate release 
tablets. Those kinds of products usually degrade immediately in 
gastrointestinal system. The developments of improved oral protein 
delivery Technology by ODTs, that dispersed and/or dissolved in the 
saliva, are very promising for the delivery of high molecular weight 
protein and peptide. 
It would be an innovative improvement in the ODT technology 
when development of ODTs with controlled release properties that can 
deliver drugs which has short half-lives like 12–24 hours. The added 
convenience and compliance of such formulations will be used more 
immensely. 
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2. LITERATURE REVIEW 
Nivedithaa V.R. et al., [2018] has studied on the obesity is known to 
have significant impact on physical and psychological health related 
issues in many countries. Combination therapy of Atorvastatin Calcium, 
a lipid lowering agent and Bisoprolol Fumarate, an antihypertensive 
agent was preferred for obesity treatment. The present research work 
was envisaged to develop immediate release tablet of Atorvastatin 
Calcium and Bisoprolol Fumarate by direct compression method to 
minimize dose dependent side effect and improve patient compliance for 
obese people. The formulation that showed more than 90% release was 
considered to be optimized formulation of combination tablet. Study 
reveals that combination of beta-blocker and statins were good candidate 
for blood pressure and lowering lipoproteins in obese patient and may 
increases patient compliance by reducing the multi dosage form therapy 
and prescription costs.34  
Safila Naveed et al., [2016] has discussed about the stability of the 
pharmaceutical formulation during its entire shelf life in its final 
packaging as an important matter. Stability study does not only cover 
the physiochemical aspects of the drug but also explains the safety and 
efficacy of the product during its entire shelf life. Force degradation 
studies are the studies in which stress conditions or accelerated 
conditions are provided to the drug in bulk or product. For the 
development of stability indicating methods especially when insufficient 
information is accessible about degradation products and to obtain 
information about the degradation pathways and degradations products 
that might affect during storage conditions forced degradation studies 
are performed. Forced degradation studies help to facilitate 
pharmaceutical development, manufacturing, production and packaging 
where knowledge of chemical behavior can be used to improve drug 
2.LITERATURE REVIEW 
 
Department of Pharmaceutics                                                                  Page 31 
 
product. An FDA and ICH regulatory body portrays the layout of these 
stability limitations for the stability and degradation point of view. 
Priyanka Patel et al., [2015] has discussed that the Studies of drug-
excipient compatibility represent an important phase in the 
preformulation stage for the development of all dosage forms. The 
potential physical and chemical interactions between drugs and 
excipients can affect the chemical, physical, therapeutical properties and 
stability of the dosage form. The present review contains a basic mode of 
drug degradation, mechanism of drug- excipient interaction like 
physical, chemical and biopharmaceutical. Different Thermal and Non-
thermal method of analysis, Tools and software for incompatibility is also 
discussed. Once the type of interaction is determined we can take further 
steps to improve the stability of drug and dosage form. From review, we 
conclude that consequent use of thermal and non-thermal method 
provide data for drug- excipient interaction which can further help in 
selection of excipient for the development of stable dosage form. 
 
Ramdooss Karthikeyan et al., (2015) described the method of analysis 
for ambrisentan in pharmaceutical dosage form by reverse phase HPLC 
using C-18 coloumn(4.6 X 250mm) and 10mM phosphate buffer(pH 6.0), 
acetonitrile(50:50, v/v) is used as mobile phase and eluents were 
monitored at 226nm. The method has shown a good linearity in 
concentration range 6-30 mg/ml. 
 
Honey Kanasara et al., (2015) described the novel technique that can 
enhance the solubility of BCS class II drug. The technique includes use 
of cosolvents, Hydrotropy, Micronization, change in dielectric constant of 
solvent, amorphous forms, chemical modification of drug, use of 
surfactants, inclusion complex, alteration of pH of solvent, use of 
hydrates or solvates, use of soluble prodrugs, application of ultrasonic 
waves, functional polymer technology, controlled precipitation 
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technology, evaporative precipitation in aqueous solution, use of 
precipitation inhibitors, solvent deposition, precipitation, selective 
adsorption on insoluble carriers. Novel drug delivery technologies 
developed in recent years for solubility enhancement of insoluble drugs 
are size reduction technologies, lipid based delivery system, micellar 
technologies, porous micro particle technology. Solid Dispersion 
Technique and various types of solid dispersion systems have also been 
explained briefly. 
 
Jishan Ali Ahmed et al., (2015) expressed various advantages 
including ease of ingestion, avoidance of pain, versatility and most 
importantly patient compliance. Sometimes immediate onset of action is 
considered obligatory immediate release tablets are the final option.  
Recently immediate release tablets have started gaining popularity and 
acceptance as a drug delivery system, mainly because they are easy to 
administer and lead to better patient compliance. In the present work, we 
engage in discussion about formulation, development and evaluation of 
immediate release tablets. They are also a tool for expanding markets, 
extending product life cycles and generating opportunities. 
 
Virender Kaur et al., (2015) studied about the disntegrants in 
Immediate drug release dosage forms disintegrate rapidly after 
administration with enhanced rate of dissolution. The basic approach 
used in development tablets is the use of superdisintegrants like Cross 
linked Polyvinylpyrrolidone or crospovidone (Polyplasdone), Sodium 
starch glycolate (Primogel, Explotab), carboxymethylcellulose 
(Croscarmellose) etc. These superdisintegrants provide instantaneous 
disintegration of tablet after administration in stomach.35 
 
Bhandari Neeraj et al., [2014] has discussed that tablet is the most 
popular among all dosage forms existing today because of its 
convenience of self administration,compactness and easy manufacturing; 
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however in many cases immediate onset of action is required than 
conventional therapy. To overcome these drawbacks, immediate release 
pharmaceutical dosage form has emerged as alternative oral dosage 
forms. There are novel types of dosage forms that act very quickly after 
adminstration. The basic approach used in development tablets is the 
use of superdisintegrants like Cross linked carboxymelhylcellulose 
(Croscarmellose), Sodium starch glycolate (Primogel, Explotab), 
Polyvinylpyrrolidone (Polyplasdone) etc. which provide instantaneous 
disintegration of tablet after administration. The development of 
immediate release tablets also provides an opportunity for a line 
extension in the market place. A wide range of drugs (e.g., cardiovascular 
drugs, analgesics, antihistamines, and drugs can be considered 
candidates for this dosage form. As a drug entity nears the end of its 
patent life, it is common for pharmaceutical manufacturers to develop a 
given drug entity in a new and improved dosage form. Immediate release 
dosage form allows a manufacturer to extend market exclusivity, while 
offering its patient population a more convenient dosage form or dosing 
regimen. Now a day, immediate release formulations are similar to many 
sustained release formulations that are now commonly available.[9] 
 
Shweta Gupta et al., [2013] has discussed that Poorly water-soluble 
drug candidates are becoming more prevalent. It has been estimated that 
approximately 60–70% of the drug molecules are insufficiently soluble in 
aqueous media and/or have very low permeability to allow for their 
adequate and reproducible absorption from the gastrointestinal tract 
(GIT) following oral administration. Formulation scientists have to adopt 
various strategies to enhance their absorption. Lipidic formulations are 
found to be a promising approach to combat the challenges. In this 
review article, potential advantages and drawbacks of various 
conventional techniques and the newer approaches specifically the self-
emulsifying systems are discussed. Various components of the self-
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emulsifying systems and their selection criteria are critically reviewed. 
The attempts of various scientists to transform the liquid self-emulsifying 
drug delivery systems (SEDDS) to solid-SEDDS by adsorption, spray 
drying, lyophilization, melt granulation, extrusion, and so forth to 
formulate various dosage forms like self emulsifying capsules, tablets, 
controlled release pellets, beads, microspheres, nanoparticles, 
suppositories, implants, and so forth have also been included. 
Formulation of SEDDS is a potential strategy to deliver new drug 
molecules with enhanced bioavailability mostly exhibiting poor aqueous 
solubility. The self-emulsifying system offers various advantages over 
other drug delivery systems having potential to solve various problems 
associated with drugs of all the classes of biopharmaceutical 
classification system(BCS).[8] 
 
Pranay Wal et al., [2013] has described that Increasing numbers of 
experimental investigations and recently also of clinical trials strongly 
suggest an integral involvement of the endothelin (ET) system in the 
pathophysiology of a variety of disease states, mainly of the 
cardiovascular system. Ambrisentan (LU208075)approved by the US 
Food and Drug Administration in 2007, a selective ETA-receptor 
antagonist, is an orally active diphenylpropionic acid derivative that was 
recently approved for treatment of pulmonary arterial hypertension (PAH) 
in patients with World Health Organization class II or III symptoms.. It 
has been shown to have a very promising efficacy to safety ratio in the 
initial clinical trials. Phase II and Phase III trials with ambrisentan in 
pulmonary arterial hypertension have been performed. Pulmonary 
arterial hypertension (PAH) is a rare and progressive disease of the 
pulmonary arterial circulation that is characterized by a progressive rise 
in pulmonary vascular resistance, eventually leading to right-heart 
failure and death. Endothelin (ET) is a potent vasoconstrictor with 
mitogenic, hypertrophic and pro-inflammatory properties. Therefore, 
2.LITERATURE REVIEW 
 
Department of Pharmaceutics                                                                  Page 35 
 
blockade of ET receptors has been suggested as an attractive target in a 
number of acute and chronic cardiovascular indications, including 
pulmonary arterial hypertension (PAH), systemic hypertension, and heart 
failure. In Phase III clinical trials in patients with PAH, ambrisentan (2.5–
10mg orally once-daily) improved exercise capacity, time to clinical 
worsening, WHO functional class, and quality of life compared with 
placebo. This review discusses the endothelin family of proteins and 
receptors and their role in the pathophysiology of pulmonary 
hypertensive diseases. 
 
Sarfaraz et al., (2013) Immediate release tablets are highly accepted fast 
growing drug delivery systems and thus, an attempt was made to 
improve the onset of action of drug. To achieve this goal, selective 
superdisintegrants croscarmellose sodium, crospovidone and sodium 
starch glycolate in different concentrations (2.5 – 7.5%w/w), were 
evaluated for their effect on the disintegration behaviour of tablets, while 
microcrystalline cellulose and lactose were used as diluents. The tablets 
were prepared by direct compression method and were evaluated for 
various physicochemical properties, FTIR, in vitro disintegration and in 
vitro drug release studies.[12] 
 
Rajesh et al., (2012) The task of developing immediate release tablet is 
accomplished by using suitable diluents and superdisintegrants. Faster 
disintegration of the tablet administrated orally minimizes absorption 
time and improves its bioavailability in less time. The formulation 
development work was initiated with wet granulation method and a total 
of 8 formulations (F1-F8) were made. The formulated tablets were 
evaluated for various pre compression parameters and post compression 
parameters like thickness, hardness, weight variation, friability, 
disintegration test, drug content uniformity and in vitro release studies. 
The formulation F8 showed satisfactory physical parameters, and it was 
found to be stable among other formulations.  
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Natarajan R et al., (2011)  to formulate various formulations of 
immediate release tablet of Paroxetine using different superdisintegrants 
(Sodium Starch Glycolate, Croscarmellose, Crospovidone) and different 
grades of di calcium phosphate by wet granulation method. The drug-
excipients interaction was investigated by FTIR. The granules and tablets 
of Paroxetine were evaluated for various pre and post compression 
parameters like Angle of repose, Compressibility index, Hausner’s ratio, 
Tablet hardness, Friability, Weight variation, Drug content and in vitro 
dissolution. Their results were found satisfactory. The in vitro dissolution 
studies show the release is in the following order of superdisintegrants: 
Sodium Starch Glycolate>Croscarmellose>Crospovidone. These results 
suggest that, as determined by f2 factor (similarity factor) and maximum 
in vitro dissolution was found to be with Formulation F-7 and it clearly 
shows due to Sodium Starch Glycolate (4%).[10] 
 
Patel N. et al., (2011)  Opadry White was used for coating the core 
tablets. Total 16 batches were formulated. In that last 6 batches were 
optimized by process parameters like kneading time, lubrication time 
and by sizing. These formulations were evaluated for physical parameters 
of tablet, drug-excipient compatibility study, and in- vitro drug release 
study. The optimize formulation F8 release profile was match with 
marketed formulation and release rate was maximum than other 
batches. Stability study of the optimized formulation indicates no 
significant differences in release profile and drug content after a period of 
one to three month. Immediate release dosage form of API was 
formulated using Cros carmellose Sodium as superdisintegrant. [11]  
Sheen et al., (1995)  studied the formulation of poorly water-soluble 
drug in solid dispersion to improve bioavailability. The results concluded 
that the bioavailability of poorly water-soluble drug was increased from 
water-soluble carrier and was further improved by the addition of a 
surfactant. 
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3.1. AIM  
The main aim of the work is to formulate immediate release 
tablets of Ambrisentan 10 mg by a direct compression method and to 
evaluate the prepared tablets against the marketed product, 
Letairis®.(Ambrisentan tablets, 10 mg) 
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3.2. OBJECTIVE 
Challenges 
➢ To develop a cost effective formulation with direct compression 
method with commercialization aspect. 
➢ Direct compression process and with limited excipients will be 
cost effective. 
➢ Low solubility of API. 
➢ To develop a robust formulation free from defects in flow and 
compression. 
➢ Since the drug load on the formulation is less than 10%, 
overcoming the challenge of blend uniformity and content 
uniformity with limited manufacturing steps is a challenge. 
➢ Attaining uniform stability results of the finished product after 
being processed. 
 
   4. Plan of Work 
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4. PLAN OF WORK 
 
❖ Literature survey.  
❖ Procurement of drug, other excipients. 
❖ Preformulation Studies[3] 
▪ Solubility 
▪ Drug and excipient compatibility studies  
▪ Bulk density 
▪ True density  
▪ Melting point determination  
▪ Carr’s index  
▪ Hausner’s ratio 
▪ Angle of repose 
❖ Formulation development  
❖ Evaluation Studies[3] 
• Weight variation 
• Hardness 
• Friability 
• Thickness 
• Disintegration time 
• Content uniformity 
• Invitro Dissolution study 
• Stability Studies 
 
5. DISEASE PROFILE 
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5. DISEASE PROFILE- PULMONARY ATREIAL HYPERTENSION 
5.1. INTRODUCTION: 
 Pulmonary aterial hypertension is a syndrome resulting from 
decreased flow of blood in the pulmonary vascualte due to increased 
pulmonary vascular resistance (PVR) and right heart failure13. The 
Revised world health organization (WHO) Classification has divided 
pulmonary hypertension into five types. The incidence of PAH is 
15/million in the population. 
Fig.No:5. Difference between Healthy and affected vessel 
 
 Pulmonary arterial hypertension is associated with increased 
PVR resulting from loss of vascular luminal cross-section due to 
vascular remodeling produced by excessive vasoconstriction plays a 
significant role in approximately 20% of patients14. Pulmonary arterial 
hypertension is a panvasculopathy predominantly affecting small 
pulmonary arteries15. Pulmonary arterial hypertension is 
characterized by a variety of arterial abnormalities including intimal 
hyperplasia, medialhypertropy, adventitial proliferation and 
thrombosis in situ. Right ventricle function is a major determinant of 
functional capacity and prognosis in PAH(1) while RV hypertrophy and 
dilation is initiated by increased after load, the adequacy of RVs 
compensatory response is quite variable amongst individuals. 
Plumonary arterial hypertension is characterized by endothelial 
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dysfunction, a decreased ratio of apoptosis/proliferation in pulmonary 
artery smooth muscle cell and thickened disordered adventitia in 
which there is excessive activation of adventitial metalloprotease16.  
Fig.No:6. Pulmonary vascular changes in PAH leading to RV strain  
 
PAH is characterized by platelets that are depleted by serotonin and 
elevation of plasma serotonin. In PAH, endothelial dysfunction is 
characterized by increased production of vasoconstrictor/mitogenic 
compounds such as endothelin and thromboxane and deficient 
production of vasodilators like prostacycline, there is also increased 
production of thromboxane A2 and deficient prostacyclin17 leading to 
thrombosis, proliferation and vasoconstriction. 
Fig.No:7. Difference between normal and affected vessel in lungs 
 
 
Decreased level of endothelial nitric oxide has been observed in PAH 
as it is quickly inactivated by PDE-5. Endothelian-1 is a 
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vasoconstrictor and a smooth muscle mithogen that may contribute to 
the development of PAH. 
 
5.2.CLASSIFICATION OF PAH AS PER WHO: 
• Pulmonary arterial hypertension 
➢ Idiopathic PAH 
➢ Familial PAH 
➢ Associated with PAH 
• Connective tissue disorder 
• Congential systemicto pulmonary shunts 
• Portal hypertension 
• Human immunodeficiency virus infection 
• Drugs and toxins 
• Pulmonary hypertension with left heart disease 
• Pulmonary hypertension associated with lung disease or 
hypoxemia 
• Pulmonary hypertension due to chronic thrombolic or embolic 
disease 
5.3.CAUSES : 
• History of heart murmur 
• Deep venous thrombosis (DVT) or pulmonary embolism (PE) 
• Raynaud phenomenon 
• Arthritis or arthralgias 
• Rash 
• Heavy alcohol consumption 
• Hepatitis 
• Heavy snoring 
• Daytime hypersomnolence 
• Morning headaches 
• Morbid obesity 
• Family history of pulmonary hypertension 
• Drug use, in particularly diet drugs and illicit drugs 
• Medications 
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5.4. SYMPTOMS: 
Patients with PAH may also have nonspecific symptoms secondary to 
pulmonary hypertension. These may include the following: 
• Dyspnea upon exertion 
• Fatigue 
• Lethargy Dizziness or fainting spells (syncope) 
• Syncope with exertion 
• Chest pain 
• Anorexia 
• Right upper quadrant pain 
• welling (edema) in your ankles, legs and eventually in your 
abdomen (ascites) 
• Bluish color to your lips and skin (cyanosis) 
• Racing pulse or heart palpitations 
 
Less common symptoms include the following: 
• Cough 
• Hemoptysis 
• Hoarseness (due to compression of the recurrent laryngeal nerve 
by the distended pulmonary artery) 
5.5. PAH Diagnosis: 
1. Blood tests: potential diseases that are associated with PAH 
as well as other signals of PAH. These include an HIV test; 
thyroid tests; autoimmune disease panels to test for systemic 
lupus erythematosus and scleroderma; liver tests; as well as 
standard tests like a complete blood count (CBC) and 
chemistry tests. It may also include a test to measure a 
hormone called brain natriuretic peptide (BNP) that helps 
evaluate the amount of stress on the heart. 
2. Chest X-ray: A chest X-ray gives a picture of heart, lung, and 
chest to look for signs of pulmonary hypertension. 
3. CT scan: A CT scan provides with a more detailed, visual 
picture of lungs, blood vessels and heart. 
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4. Electrocardiogram: This noninvasive test shows the electrical 
activity of the heart and can detect abnormal heart rhythms. It 
is a useful test to identify different causes for symptoms 
associated with PAH. 
5. Pulmonary function tests: These simple breathing tests 
measure how much air you can hold in your lungs and how 
much air moves in and out of your lungs.  
6. Exercise tolerance test (also known as the 6-minute walk 
test): This test is used to compare exercise capacity, oxygen 
levels and symptoms over time and to evaluate how these 
characteristics change over time and with therapy. 
7. Cardiopulmonary exercise testing (CPET or CPX): This test 
measures how well heart and lungs are performing both at 
rest and during exercise. CPET helps to understand the 
amount of oxygen your body is using, the amount of carbon 
dioxide body is producing, and the breathing pattern.  
8. Ventilation-perfusion scan (VQ scan): This test examines air 
and blood flow to the lungs and creates images use to look for 
blood clots in the lungs. 
9. Echocardiogram: This noninvasive test – a type of ultrasound 
of the heart – looks at the chambers and valves of the heart, 
determining their size and function. An echocardiogram will 
detect some signs of PH in most patients with the disease, 
making it very practical. While it does not directly measure 
pulmonary arterial pressure (PAP), it does give an idea if PH is 
present and how severe it is. Unfortunately, it cannot 
guarantee the diagnosis of PH by itself, which means further 
testing is likely. 
10. Cardiac MRI (Magnetic Resonance Imaging): This is an MRI 
test that evaluates the heart size and function more accurately 
than the echocardiogram and gives a better picture of the 
heart muscles, valves, and blood work. It may also show any 
5. DISEASE PROFILE 
 
 
Department of Pharmaceutics                                                             Page 45 
  
congenital heart disease (an abnormality in the heart that 
developed before birth). 
11. Right-sided heart catheterization: will likely recommend a 
right-sided heart catheterization because it is the clearest test 
for showing which of the five forms of PH. This test involves 
placing a small tube, known as a catheter, into a large vein in 
the neck, arm, or groin. This catheter is then threaded 
through the different chambers of the heart and lung to 
measure the pressure in each. How much blood the heart 
pumps each minute, known as cardiac output, is also 
measured. The amount of resistance to blood flow in the 
lungs, known as the pulmonary vascular resistance, can be 
calculated from these measurements and are important 
indicators of how severe PAH is. 
 
5.6. TREATMENT:  
A) MEDICATION: 
1. Calcium Channel Blockers:  Nifedipine, Diltiazem, Amlodipine 
2. Vasodilators: Epoprostenol, Treprostinil, Iloprost 
3. PAH, Prostacyclin Agonists:  Selexipag 
4. Endothelin-Receptor Antagonists : Bosentan, Ambrisentan, 
Macitentan 
5. Phosphodiesterase-5 Enzyme Inhibitors :  Sildenafil, 
Tadalafil, Vardenafil  
6. Soluble Guanylate Cyclase (sGC) Stimulators: Riociguat 
7. Cardiac Glycosides: Digoxin  
8. Loop Diuretics : Furosemide, Bumetanide    
9. Anticoagulants: Warfarin  
10. Oxygen. 
B) SURGERY:  
• Atrial septostomy. If medications don't control pulmonary 
hypertension, this open-heart surgery might be an option. In an 
atrial septostomy, a surgeon will create an opening between the 
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upper left and right chambers of heart (atria) to relieve the 
pressure on the right side of heart. Atrial septostomy can have 
serious complications, including heart rhythm abnormalities 
(arrhythmias). 
• Transplantation. In some cases, a lung or heart-lung transplant 
might be an option, especially for younger people who have 
idiopathic pulmonary arterial hypertension. 
Major risks of any type of transplantation include rejection of the 
transplanted organ and serious infection, and you must take 
immunosuppressant drugs for life to help reduce the chance of 
rejection. 
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6. DRUG PROFILE - AMBRISENTAN 
Description: 
Ambrisentan, is an orally active endothelin 
receptor antagonist that is selective for the endothelin type-A (ETA) 
receptor antagonist indicated for the treatment of pulmonary arterial 
hypertension. As an endothelin receptor antagonist, Ambrisentan 
prevents endogenous endothelin peptide from constricting the 
muscles in blood vessels, allowing them to relax and permit a 
reduction in blood pressure. It contains a single chiral center 
determined to be the (S) configuration. Ambrisentan was approved by 
the U.S. Food and Drug Administration (FDA) and European 
Medicines Agency, and designated an orphan drug, for the treatment 
of pulmonary hypertension. 
Chemical Structure 
CAS number 
177036-94-1 
 
IUPAC Name 
 (S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-
oxazolidin-2-one 
Description 
 White to off- white powder 
Drug class 
Pulmonary Arterial Hypertension Agents 
BSC Classification Class II 
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Water Solubility 
Ambrisentan is practically insoluble in aqueous solutions at low 
pH. Solubility increases at higher pH. 
pKa  4 
Molecular weight: 378.428 g/mol 
Pharmacodynamics: 
 Ambrisentan is an orally active, non-sulfonamide, propanoic –
class, endothelin receptor antagonist (ERA) that is selective for 
endothelin type A (ETA) receptor. ETA receptor antagonist inhibit 
phospholipase C-mediated vasoconstriction and protein kinase C-
mediated cell proliferation, while preserving nitric oxide and 
prostacyclin production, cyclic GMP- and cyclic AMP –mediated 
vasodilation, and endothelin-1 (ET-1) clearance that is associated with 
the endothelin type B (ETB) receptor. ERAs have proven therapeutic 
benefit in treatment of PAH in humans.Ambrisentan has a high 
affinity against myocardial native ETA receptor, with selectivity for the 
ETA receptor of approximately 4000-fold relative to the ETB receptor.  
 It is indicated for treatment of idiopathic (‘primary’) pulmonary 
arterial hypertension (IPAH) and pulmonary arterial hypertension 
(PAH) associated with connective tissue disease in patients with WHO 
functional class II or III symptoms. 
Pharmacokinetics: 
Absorption: 
 Ambrisentan was well absorbed following oral administration. It 
also showed high absolute oral bioavailability, indicating that it 
undergoes little or no first pass metabolism. Cmax occurring around 
1.5 hours post dose under both fasted and fed condition. Cmax and 
AUC increase dose proportionally over the therapeutic dose range. 
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Distribution: 
 Ambrisentan binds to plasma proteins to a higher extent 
(98.9%) and specifically albumin was the primary binding protein.  
Metabolism: 
 Ambrisentan is metabolized by phase I oxidative metabolism 
and by phase II hepatic glucuronidation. About 30% of the 
administered dose undergo oxidative metabolism mainly by CYP3A4 
and to a lesser extent by CYP3A5 and CYP2C19. The identified 
metabolites of ambrisentan includes  
• 4,6 dimethyl-2-hydroxypryimidine(M1) 
• Ambrisentan glucuronide (M2) 
• Hydroxylated ambrisentan (M3) 
• O-demethylated ambrisentan (M4) 
• Dihydroxylated ambrisentan (M5) 
• Dihydroxylated ambrisentan glucuronide (M6) 
• Hydroxylated ambrisentan glucuronide (M7) 
• O-demethylhydroxymethyl ambrisentan (M8) 
Excretion: 
The  major route of elimination of elimination for ambrisentan 
and its metabolites is biliary excretion in faeces (65.4%), with urinary 
excretion (22.1%) representing minor route. 
Drug indication: 
Ambrisentan is indicated for the treatment of pulmonary arterial 
hypertension (PAH) (WHO Group 1): 
• To improve exercise ability and delay clinical worsening. 
• In combination with tadalafil to reduce the risks of disease 
progression and hospitalization for worsening PAH, and to 
improve exercise ability. 
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Studies establishing effectiveness included predominantly 
patients with WHO Functional Class II–III symptoms and etiologies of 
idiopathic or heritable PAH (60%) or PAH associated with connective 
tissue diseases (34%). 
DOSAGE AND ADMINISTRATION: 
Adult Dosage 
Initiate treatment at 5 mg once daily, with or without tadalafil 
20 mg once daily. At 4-week intervals, either the dose of Letairis or 
tadalafil can be increased, as needed and tolerated, to Ambrisentan 10 
mg or tadalafil 40 mg. 
SIDE EFFECTS: 
Clinically significant adverse drug reactions that appear                
which includes, 
• Embryo-fetal Toxicity  
• Fluid Retention  
• Pulmonary Edema with PVOD  
• Decreased Sperm Count  
• Hematologic Changes  
Brand names 
 Letairis®(Ambrisentan tablets) 10 mg 
Uses: 
Ambrisentan is indicated for the treatment of pulmonary arterial 
hypertension (WHO Group 1) in patients with WHO class II or III 
symptoms to improve exercise capacity and delay clinical worsening. 
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7. EXCIPIENT PROFILE 
7.1 CROSCARMELLOSE SODIUM[20] 
Synonym :   
Ac-Di-Sol;Crosslinkedcarboxymethylcellulose sodium; Modified 
cellulose gum; Pharmacel XL; carmellosumnatricumconexum. 
Description : White odorless or greyish white powder. 
Structure : 
 
 
 
 
 
 
IUPAC name: Acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium 
Chemical name: 
 Croscarmllose; Sodium Carboxymethylcellulose; Carmellose 
Molecular formula : C28H30Na8O27 
Molecular Weight  : 982.44 g/mol 
Solubility: 
 Insoluble in water, although croscarmellos Sodium rapidly swells 
to 4–8 times its original  volume on contact with water. Practically 
insoluble in acetone, ethanol and toluene. 
Safety : 
It is a nontoxic and nonirritant material. However, oral  
consumption of large amounts of croscarmellose sodium may havea 
laxative effect, although the quantities usedin solid dosage formulations 
are unlikely to cause such problems. 
Application 
• Disintegrant for capsules, tablets, and granules 
• Disintegrant in tablets : 0.5 – 5.0 % 
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• Disintegrant in capsules : 10 – 25 % 
Stability and storage conditions: 
• Croscarmellose sodium is a stable though hygroscopic material. 
• Croscarmellose sodium should be stored in a well-closed container 
in a cool, dry place. 
 
7.2. LACTOSE MONOHYDRATE[20] 
 
Synonym:  
CapsuLac; GranuLac; Lactochem; lactosummonohydricum; 
Monohydrate; Pharmatose; PrismaLac; SacheLac; SorboLac; SpheroLac; 
Super Tab 30GR; Tablettose. 
Description:     
 Lactose occurs as white to off-white crystalline particles or powder. 
Lactose is odorless and slightly sweet-tasting; a-lactose is approximately 
20% as  sweet as sucrose, while b-lactose is 40% as sweet 
Structure : 
 
 
 
 
 
IUPAC name:  
(2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6[(2R,3S,4R,5R)-4,5,6-
trihydroxy-2-(hydroxymethyl)oxan-3yl] oxyoxane-3,4,5-triol 
Chemical name:  
O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose monohydrate 
Molecular formula : C12H22O11H2O 
Molecular Weight  : 360.31 
Solubility : Practically insoluble in chloroform, ethanol, ether. 
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Water   
• 1 in 5.24 
• 1 in 3.05 at 400C 
• 1 in 2.30 at 500C 
• 1 in 1.71 at 600C 
• 1 in 0.96 at 800C 
  
Melting point : 201–2020C 
Applications  : 
Lyophilization aid, Tablet binder, Tablet and capsule diluent, 
Tablet and capsule filler. 
Storage :   
Mold growth may occur under humid conditions (80% relative 
humidity and above). Lactose may develop a brown coloration on storage, 
the reaction being accelerated by warm, damp conditions; Lactose should 
be stored in a well-closed container in a cool, dry place. 
 
7.3. MICROCRYSTALLINE CELLULOSE[20] 
 
Synonym :  
Avicel PH; Cellulose gel; Crystallinecellulos; E460; Emcocel; 
Fibrocel; Tabulose; Pharmacel. 
Description :  
Microcrystalline cellulose is a purified, partially depolymerized 
cellulose that occurs as a white, odorless, tasteless, crystalline powder 
composed of porous particles 
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Structure : 
 
 
IUPAC name:       
2-[4,5-dihydroxy-2-(hydroxymethyl)-6-methoxyoxan-3-yl]oxy-6-
(hydroxymethyl)-5-methoxyoxane-3,4-diol 
Chemical name: Cellulose gel; Cellulose, microcrystalline 
Molecular formula: C14H26O11 
Molecular Weight :370.351 g/mol 
Solubility :  
Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents 
Melting point : Chars at 260–2708C. 
 
 
Applications : 
Adsorbent, Suspending agent, Tablet and capsule diluent, Tablet 
disintegrant 
Safety : 
Microcrystalline cellulose is widely used in oral pharmaceutical 
formulations and food products and is generally regarded as a relatively 
nontoxic and nonirritant material. 
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Storage :  
Microcrystalline cellulose is a stable though hygroscopic material. 
The bulk material should be stored in a well-closed container in a cool, 
dry place. 
 
7.4. MAGNESIUM STEARATE[20] 
Synonym :   
Dibasic magnesium stearate; magnesium distearate; magnesia  
stearas; magnesium octadecanoate; octadecanoic acid, magnesiumsalt; 
stearic acid, magnesium salt; Synpro 90. 
Description :  
Magnesium stearate is a very fine, light white, precipitated or 
milled, impalpable powder of low bulk density, having a faint odor of 
stearic acid and a characteristic taste. The powder is greasy to the touch 
and readily adheres to the skin. 
Structure : 
 
 
IUPAC name :      Magnesium; octadecanoate 
 
Chemical name :          
Magnesium stearate; Magnesium octadecanoate; Magnesium 
distearate; Synpro 90; Octadecanoic acid,  
Molecular formula : C36H70MgO4 
Molecular Weight : 591.24 g/mol 
Solubility :  
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Practically insoluble in ethanol, ethanol (95%), ether and water; 
slightly soluble in warm benzene and warm ethanol (95%).                    
Melting point : 117–1500C 
Applications : Tablet and Capsule Lubricant 
Safety :  
It is generally regarded as being nontoxic following oral administration. 
However, oral consumption of large quantities may produce a laxative 
effect or mucosal irritation. 
Storage:  
Magnesium stearate is stable and should be stored in a well-closed 
container in a cool, dry place. 
8. MATERIALS AND EQUIPMENTS USED 
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8. MATERIALS AND EQUIPMENTS USED 
8.1. Active pharmaceutical Ingredient 
Table 2. Active Pharmaceutcal Ingredient and its manufacturer. 
API Manufacturer 
Ambrisentan Aurobindo Pharma 
 
8.2. Excipients 
Table 3. Excipients and its manufacturers. 
Excipients Manufacturer 
Lactose Monohydrate SPI Pharma 
Microcrystalline cellulose PH101 Roquette Pharma 
Croscarmellose sodium Avantor Performance Materials 
Magnesium Stearate Firmenich Pharma 
 
8.3.Equipments used: 
➢ Analytical balance, 
➢ Sieves, 
➢ Proton mini press compression machine, 10 station, 
➢ vernier calliper, 
➢ Electrolab Friability tester, 
➢ Hardness tester, 
➢ Electrolab Tap Density Tester,  
➢ Electrolab Disintegration Tester, 
➢ Ohaus Moisture analyser, 
➢ Funnel and stand for Angle of repose, 
➢ UV spectrophotometry, 
➢ Dissolution test apparatus,  
➢ Water's HPLC 
 
  
 
9. PREFORMULATION 
 
 
 
 
 
Department of Pharmaceutics                                                            Page 58 
 
9. PREFORMULATION 
It is the first step in rational development of dosage forms of 
drug substance. Preformulation testing is defined as investigation of 
physical and chemical properties of a drug substance alone and when 
combined with excipients. The overall objective of preformulation 
testing is to generate information useful to the formulator in 
developing stable and bio-available dosage forms that can be mass-
produced. Preformulation investigations are designed to identify those 
physicochemical properties and excipients that may influence the 
formulation design, method of manufacture and pharmacokinetic 
biopharmaceutical properties of the resulting product. 
 
Preformulation parameters 
9.1.Organoleptic properties 
This includes recording of appearance,colour, odour and taste of 
the drug using descriptive terminology. Record of colour of early 
batches is very useful in establishing appropriate specifications for 
later production. Colour white. 
 
9.2.Physicochemical characterization: 
9.2.1.Density measurement: 
Granules density may influence compressibility, tablet porosity, 
dissolution and other properties. Different types of density calculation 
were done to characterize the API and its flow property. Generally two 
types of density are determined i.e., bulk density and tapped density. 
The methods followed for calculation of the above two densities are 
determined by the following ways. 
 
9.2.2.Bulk density:  
 It is a measure used to describe the packing of particles or 
granules. An accurately weighed quantity of powder, which was 
previously passed through sieve #40 [USP] and carefully poured bed 
was made uniform without disturbing. Then volume measure was 
called as the bulk volume and the bulk density is calculated by 
following formula. 
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Bulk density= weight of powder / Bulk volume 
 
9.2.3.Tapped density: 
 After measuring the bulk volume the same measuring cylinder 
was set into tap density apparatus. The tap density apparatus was set 
to300 taps drop per minute and operated for 500 taps. Volume was 
noted as (Va)and again tapped for750 times and volume was noted as 
(Vb). If the difference between Va and V b not greater than 2% then Vb is 
considered as final tapped volume. The tapped density is calculated by 
the following formula. 
Tapped density= Weight of powder /Tapped volume 
 
9.2.4.Flow properties:  
The flow properties from a material result from many forces. 
There are many types of forces hat can act between solid particles: 
frictional forces, surface tension forces, mechanical forces caused by 
interlocking of particles of irregular shapes, electrostatic forces and 
cohesive or van der vaals forces. These forces can effect granule 
properties such as particle size, particle size distribution, particle 
shape, surface texture or roughness, residual surface energy and 
surface area. 
 
9.2.5.Compressibility index: 
 Pharmaceutical powders are broadly classified into free flowing 
and cohesive.  Powders are more often compressed into tablets using a 
pressure of 5kg/cm2.  This is called compression or compaction. 
During this process the porosity of the powder changes. The 
compression properties of most drugs are very poor.  Therefore 
compression vehicles such as lactose, calcium phosphate and 
microcrystalline cellulose are included in tablet formulations.  
Normally low dose drugs (<50mg) are prepared by direct compression. 
Tablet materials should be plastic that is capable of undergoing 
permanent deformation yet exhibit brittleness.  Percentage 
compressibility also known as Carr’s consolidation index is indirectly 
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related to the relative flow rate, cohesiveness and particle size.  It is a 
simple, fast and popular method for predicting powder flow 
characteristics. 
Table 4. compressibility and flowability. 
Percentage  compressibility Flowability 
5-10 Excellent 
12-16 Good 
18-21 Fair 
23-25 Poor 
 
Carr’s consolidation index= [(Tapped density-Fluff density)/tapped 
density]*100  
Compressibility index can be a measure of the potential 
strength that a powder could build up in its arch in a hopper and also 
the ease with which such an arch should be broken. 
 
9.2.6.Angle of repose 
The angle of Repose is defined as the maximum angle possible 
between the surface of a pile of powder and the horizontal plane.  
θ= Tan-1 (h/r) 
Where  
          ‘h’    =     height of the pile 
                 ‘r’    =     radius of the pile 
Values of Ө are rarely less than 200, and values of up to 400 
indicate reasonably flow potential. Above 500, however, the powder 
flows only with great difficulty.  In general, the angle of repose 
increased with decreasing particle size. The addition of talk in low 
concentration decreases the repose angle, but in higher concentration 
it increases the angle.  
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Table 5. Flow Properties and Corresponding Angles of Repose 
Flow Property Angle of Repose (degree) 
Excellent 25-30 
Good 31-35 
Fair – aid not needed 36-40 
Passable -  may hang up 41-45 
Poor – must agitate, vibrate 46-55 
Very poor 56-65 
Very very poor >66 
 
9.2.7.Hausner ratio 
It is the ratio of bulk volume or tapped density to bulk density. 
Hausner’s ratio is an important character to determine the flow 
property of powder and granules. Thiscan be calculated by the 
formula 
Hausner ‘s ratio=Tapped density/Bulk density 
Value <  1.25 indicate good flow (=20% carr’s index) 
While > 1.50 indicate poor flow (-35% carr’s index) 
Table 6. Flow property and corresponding Hausner’s ratio. 
Flow Character Hausner’s Ratio 
Excellent 1.2-1.3 
Good 1.3-1.4 
Fair 1.4-1.5 
Poor 1.5-1.6 
 
9.2.8.Particle size distribution 
Particle size distribution is a very important in process 
technique of final blend after blending. It is an important parameter to 
determine the amount of fines as well as particle with larger particle 
size in final blend. It also helps in keeping a check over uniformity of 
distribution of blend over various sizes while carrying out consecutive 
batches. Particle size determination was carried by arranging various 
sieves of sizes #20, #40, #60, #80, #100, #140, #200 and Pan (for finer 
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particles which passes even #200 sieve) in ascending order (i.e.,#20 
sieve lies on top and pan at the bottom). Then the final blend of 
accurately weighed quantity was placed on the top sieve. And the 
sieves are placed in vibrosifter and allowed to run at 1.0 amplitude for 
10 minutes. After the procedure difference of initial and final weight of 
sieves were noted to calculate the percentage retention of the blend in 
various sieves. 
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10. FORMULATION 
Batches and their composition: 
Various batches were planned and executed with the unit 
concentration of the ingredients used in the batch as shown in the 
table below. 
Table 7. Composition of unit dose of various trial batches. 
S.No Ingredients F1 F2 F3 F4 F5 F6 F7 
1 Ambrisentan 10 10 10 10 10 10 10 
2 Lactose Monohydrate 98 91 84 77 70 63 56 
3 
Microcrystalline 
cellulose pH 
101(MCC) 
14 21 28 35 42 49 56 
4 
Croscarmellose 
sodium (CCS) 
15 15 15 15 15 15 15 
5 Magnesium stearate 3 3 3 3 3 3 3 
Total 140 140 140 140 140 140 140 
Procedure: 
1. Weigh the API and excipients as per the above formula. 
2. Sift the item #01, 02, 03 in #30 mesh. 
3. Blend all the ingredients. 
4. After blending the above mixture is prelubricated with 
magnesium stearate. 
5. Collect pooled sample blend for characterization. 
6. Compress the final blend in a protn mini press rotary tablet 
press with a target weight of 140 mg. 
7. Collect the tablets, pick the tablets randomly and evaluated. 
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11. EVALUATION. 
11.1.Physical appearance 
The physical appearance of a tablet, its visual identity and over 
all “elegance” is essential for consumer acceptance. Included in this 
category are tablet sizes, shape, colour, presence or absence of any 
odour, taste, surface texture, physical flaws and consistency and 
legibility of any identification marking. 
11.2.Weight variation 
Twenty tablets were selected randomly from the lot and weighed 
individually to check for weight variation. Each tablet weight was then 
compared with average weight variation. Each tablet weight was then 
compared with average weight to ascertain the weight of the tablets 
within the permissible limits. Not more than two of the individual 
weights should deviate from the permissible limits. Not more than two 
of the individual weights should deviate from the average weight by 
more than 5% for >300mg tablets and none by more than double that 
percentage.  
Percentage deviation= [(Tablet weight- Average weight)/tablet 
weight]*100 
Table.8 USP Specification for uniformity of weight. 
S.No Weight (mg) Maximum percentage 
difference allowed 
1. 130 or Less 10 
2. 130 - 324 7.5 
3. More than 324 5 
11.3.Loss on drying 
Loss on drying is an important parameter to determine the 
moisture intake by blend during processing. Limit on loss on drying is 
established from the sum of percentage moisture intake values of each 
excipients used in the process. Percentage moisture in take was 
determined during in process by using Ohaus Moisture Analyser. In 
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which 1gm of blend was placed after taring the instrument at 105°C in 
auto mode. 
11.4.Friability 
Friability test is performed to assess the effect of friction and 
shocks, which may often cause the tablet to chip, cap or break. Roche 
friabilator was used for the purpose. This device subjects number of 
tablets to the combined effect of abrasion and shock by utilizing a 
plastic chamber that revolves at 25 rpm dropping the tablets at a 
distance of 6 inches with each revolution. Pre-weighed sample of 
tablets were dusted and reweighed. Compressed tablets should not 
lose more than 1% of their weight. 
Percentage friability=[(w2-w1)/w1]*100 
Where, W1= Weight of tablets before test;  W2= Weight of tablets after 
test 
11.5.Thickness 
The thickness was measured by using vernier calliper and 
values were tabulated. Ten tablets of each batch were measured. 
Average and standard deviation was calculated. 
11.6.Hardness 
The hardness of tablet is an indication of its strength. 
Measuring the force required to break the tablet across tests it. The 
force is measured in kg and the hardness of about 3-5 kg/cm2 is 
considered to be satisfactory for uncoated tablets. Hardness of 10 
tablets from each formulation is determined by Erweka hardness 
tester. 
11.7.Disintegration test 
Breaking of tablets into smaller particles or granules is known 
as disintegration and time taken for breaking of tablets in a suitable 
medium is called disintegration time (DT). This test is not applicable 
to modified-release tablets and tablets for use in the mouth. For those 
tablets for which the dissolution test is included in the individual 
monograph, the test for disintegration is not required. It is determined 
by USP apparatus. It consists of 6 glass tube each 3 inches long, open 
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at top and has 10 mesh screens at the bottom end of basket rack. One 
tablet is placed in each tube and placed in a one litre beaker of water, 
simulated gastric fluid or simulated intestinal fluid at 37 ± 2oC. It 
moves up and down through a distances of 5 to 6 cm at 28 to 32 cpm.  
Uncoated tablet has disintegration time as low as 5 minutes. 
Majority of tablets has DT of 30 minutes. DT of enteric coated tablet is 
one hour in simulated gastric fluid and two hours in simulated 
intestinal fluid.  DT for dispersible and soluble tablets is within 3 
minutes. 
11.8.Wetting time and water absorption ratio:  
Wetting time of dosage form is related to with the contact angle. 
Lower wetting time implies a quicker disintegration of the tablet. 
Wetting time: 
It is closely related to the inner structure of the tablets and to 
the hydrophilicity of the excipients. To measure wetting time, five 
circular tissue papers of 10cm diameter are placed in a petridish with 
a 10cm diameter. 10ml of water containing eosin, a water soluble dye, 
is added to petridish. A tablet is carefully placed on the surface of the 
tissue paper. The time required for water to reach upper surface of the 
tablet is noted as a wetting time. 
Water absorption ratio:   
A piece of tissue paper folded twice was placed in a small Petri 
dish containing 6 ml of water. A tablet was put on the paper & the 
time required for complete wetting was measured. The wetted tablet 
was then weighed. The water absorption ratio, R can be the 
determined according to the following equation; 
R = 100 (Wa-Wb) / Wb 
Where,  
Wb; The weight of the tablet before keeping in the petridish. 
Wa; The wetted tablet from the petridish is taken and 
reweighed. 
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11.9. Analytical methods 
Method of analysis for Dissolution 
Dissolution Parameters 
Table 9. Dissolution parameters 
Apparautus USP Apparatus 2 (paddle) 
RPM 75 RPM 
Dissolution medium pH 5.0 Acetate buffer,  
900ml 
Time 5,10,15(Q),30 and 45 minutes 
Sample collection volume 10 mL 
Temperature 37.0±0.5°C 
λ max 262 nm 
Procedure 
➢ Randomly select and weigh six tablets individually. Record the 
weight of each tablet. 
➢ Run the dissolution test on six tablets by applying the 
parameters in the table. 
➢ Withdraw sample solution portion of about 10 mL in each 
dissolution vessel at the specified time point. 
➢ Filter through a 0.45µ PVDF filter by discarding the first 4 mL of 
the filtrate.  
➢ Sample is analysed by using UV spectrophotometer. 
 
11.10.STABILITY STUDIES: 
➢ The optimized formulation is subjected to stability study as per 
ICH guidelines to assess their stability with respect to their 
physical appearance and release characteristics. 
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11.11.Method of analysis for Assay 
Chromatographic parameters 
Table 10. Chromatographic parameters for Assay. 
Mobile phase Buffer and acetonitrile (45:55) 
Column X Bridge, C18, 150x4.6mm, 5.0µ Particle Size 
Manufacturer: Waters, Part no:186003116 
Flow rate 1.0mL/min 
Sample 
temperature 
Ambient 
Column 
temperature 
30°C 
Wavelength 220nm 
Injection volume 20µL 
Run time 10 minutes 
Sample retention 
time 
About 4.5 minutes 
System 
suitability 
The RSD of Zolmitriptan peak area is NMT 2.0% 
The USP tailing factor for ambrisentan peak is 
NMT 2.0from standard preparation. 
The USP plate count for ambrisentan peak , NLT 
3000 from standard preparation. 
Chromatographic procedure 
➢ Perform an injection of diluent preparation. 
➢ Perform five (5) replicate injections of the standard preparation. 
➢ USP Tailing factor for Ambrisentan peak is NMT 2.0. 
➢ The relative standard deviation (RSD) of the peak area is not 
more than 2.0% for Ambrisentan in standard preparation. 
➢ Perform an injection of test solution in duplicates. 
➢ Record the chromatograms and calculate the percentage of 
Ambrisentan dissolved as per the formula 
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Percentage Assay 
=
𝐴𝑡
𝐴𝑠
×
𝑊𝑠
100
×
5
50
×
𝑉1
𝑊𝑇
×
𝑉3
𝑉2
×
𝑃
100
×
𝑇𝑊
𝐿𝐶
× 100 
Where, 
At = Peak area of ambrisentan from the chromatogram of the assay 
preparation. 
As = Average peak area of ambrisentan from the chromatograms of 
the standard      solution. 
Ws = Weight of Ambrisentan WRS taken in mg. 
WT =Weight of blend sample taken in mg. 
P = Potency of Ambrisentan WRS on as is basis. 
LC = Label claim of Ambrisentan tablet, in mg. 
V1 =Respective volume of the standard volumetric flask used for 
sample stock preparation in ml. 
V2 =Respective volume of sample pipetted in ml. 
V3 =Respective volume of volumetric flask used for sample 
preparation in mL. 
11.12.Content Uniformity 
=
𝐴𝑡
𝐴𝑠
×
𝑊𝑠
100
×
5
50
×
𝑃
100
×
𝑉
𝐿𝐶
× 100 
Where, 
At = Average peak area of Ambrisentan from the chromatograms of 
the sample solution. 
As = Average peak area of Ambrisentan from the chromatograms of 
the standard solution 
Ws = Weight of Ambrisentan WRS taken in mg. 
P = Potency of Zolmitrptan WRS on as is basis. 
LC = Label claim of Zolmitriptan tablet, in mg. 
V =Respective volume of the standard volumetric flask used for 
sample preparation in mL. 
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11.13.Method of Analysis for Impurities and Degradants 
Chromatographic parameters 
Table 11. Chromatographic parameters for Impurities and 
degradants. 
Mobile phase Mobile phase A= Buffer  
Mobile phase B= Acetonitrile 
Column Sunfire C18,4.6 x 250 mm, 5.0 µm particle size 
Gradient 
Time 
Mobile phase 
A (%) 
Mobile phase 
B (%) 
0 50 50 
5 50 50 
15 32 68 
20 25 75 
25 25 75 
30 50 50 
40 50 50 
Flow rate 1.0 mL/min 
Sample temperature Ambient 
Column temperature 35°C 
Wavelength 220nm 
Injection volume 10µL 
Run time 40 minutes 
Sample retention 
time 
About 12 minutes 
Sample preparation Sample preparations containing Ambrisentan 
about 1000 µg/mL. 
System suitability The RSD of Ambrisentan peak area is NMT 5.0% 
from standard solutions. 
The theoretical plate count for Ambrisentan is 
not less than 5000 from standard solution. 
The tailing factor for Ambrisentan is not more 
than 2.0 from standard solution 
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Chromatographic procedure 
➢ Perform an injection of diluent preparation. 
➢ Perform five (6) replicate injections of the standard preparation. 
➢ The relative standard deviation (RSD) of the peak area is not 
more than 5.0% for Ambrisentan peak in standard preparation. 
➢ The theoretical plate count for Ambrisentan should not be less 
than 5000. 
➢ The tailing factor for Ambrisentan should not be more than 2.0. 
➢ Perform an injection of placebo solution. 
➢ Perform an injection of test solution. 
➢ Record the chromatograms and calculate the percentage of 
impurities and degradants as per the formula. 
Calculations 
Percentage of known impurity:       
=
𝐴𝑇1
𝐴𝑆
×
𝑊𝑆
100
×
5
100
×
50
𝑊𝑇
×
𝐴𝑊
𝐿𝐶
×
𝑃
100
× 𝑅𝐹 × 100 
Percentage of Known impurity 
=
𝐴𝑇2
𝐴𝑆
×
𝑊𝑆
100
×
5
100
×
50
𝑊𝑇
×
𝐴𝑊
𝐿𝐶
×
𝑃
100
× 100 
Where, 
At1 = Peak area of known impurity from the chromatogram of the 
sample solution. 
At2 = Peak area of unknown impurity from the chromatogram of the 
sample solution. 
As = Mean peak area of Ambrisentan from the chromatograms of 
the standard      solution. 
Ws = Weight of Ambrisentan WRS taken in mg. 
Wt = Weight of Ambrisentan tablets powder taken in mg. 
Avg.wt= Average weight of tablets in mg. 
P = Potency of Ambrisentan WRS on as is basis. 
RF = Response Factor of the known impurity. 
LC = Label claim of Ambrisentan tablet, in mg. 
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12. RESULT AND DISCUSSION 
12.1.Pre formulation Studies: 
 
API Characteristics 
Bulk density    :  0.291 g / mL 
Tapped density    :  0.641 g / mL 
Compressibility index   :  54.60 
Hausner ratio    :  2.20 
PSD by Malvern master Sizer  :  
     d10  :  6.7 microns 
     d50  :  31.4 microns 
             d90  :  143.3 microns 
API Manufacturer   : Zhezianghuahai pharmaceutical Co., Ltd 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12. RESULT AND DISCUSSION 
 
Department of Pharmaceutics                                                                 Page 73 
  
Table .No: 12. API Solubility 
 
Water 
 
 
0.1N HCL 
Solubility 
(mg/ml) 
Solution Stability 
(% degradation) 
Solubility 
(mg/ml) 
Solution Stability 
(% degradation) 
 
24hrs 
 
48hrs 
 
24hrs  
 
 
48hrs 
0.04670 
0.0470
6 
0.04661 0.03948 0.03664 0.03349 
 
 
pH 3.0 Buffer  
pH 4.5 Acetate buffer 
Solubilit
y 
(mg/ml) 
Solution Stability 
(% degradation) 
Solubility 
(mg/ml) 
Solution Stability 
(% degradation) 
 
24hrs 
 
48hrs 
 
24hrs  
 
 
48hrs 
0.01812 0.01732 0.01626 0.10183 0.10182 0.10010 
 
 
pH 5.0 Acetate buffer 
 
 
pH 6.8 Phosphate buffer 
 
Solubility 
(mg/ml) 
Solution Stability 
(% degradation) 
Solubility 
(mg/ml) 
SolutionStability 
(% degradation) 
 
24hrs  
 
 
48hrs 24hrs 48hrs 
0.25395 0.25479 0.25204 3.98 4.00 3.97 
 
 
pH 8.5 Borate buffer 
 
Solubility 
(mg/ml) 
Solution Stability 
(% degradation) 
24 hrs 
 
48hrs 
 
14.81 14.94 14.80 
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Based on the above results it is clear that Ambrisentan is less 
soluble in acidic pH and the solubility increased with increase in pH. 
 
12.2.RLD Characteristics 
Letairis®(Ambrisentan tablets, 10 mg) 
Lot# SBFW 
Exp Date   : 09/2018 
Manufactured by  : Gilead sciences, Inc. Foster City, CA 
94404 
Pack    : Bottle containing 3 tablets stored in a  
HDPE container with dunnage. 
Average Tablet Weight :       148.8 mg 
Average thickness : 3.28 mm 
Average Hardness : 12 kP 
Dissolution  
Table 13. Percentage drug dissolved in RLD. 
Time (minutes) Mean % Drug Dissolved 
5 65 
10 72 
15 85 
30 91 
45 98 
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12.3.EVALUATION ON PRECOMPRESSION PARAMETERS: 
Characteristics of final blend: 
Final blend was characterized with various parameters like bulk 
density, tapped density, angle of repose and loss on drying for each batch 
and their results were tabulated below 
Table 14. Result for bulk density, tapped density, angle of repose 
and loss on drying for the trial batches. 
Particulars F1 F2 F3 F4 F5 F6 F7 
Bulk 
density 
(g/mL) 
0.56 0.60 0.54 0.56 0.60 0.58 0.61 
Tapped 
density 
(g/mL) 
0.44 0.43 0.34 0.40 0.40 0.39 0.40 
Angle of 
repose 
Ø 
36 39 37 32 33 32 33 
% LOD 4.5 5.4 2.9 3.0 2.7 2.8 2.9 
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Particle Size Distribution 
Particle Size Distribution for final blend of the trial batches were 
performed and the results are tabulated below 
Table 15. Particle size distribution results for the final blend of trial 
batches. 
Particulars F1 F2 F3 F4 F5 F6 F7 
20 0 0 0 0 0 0 0 
40 4 4 2 2 0 2 2 
60 14 12 16 14 12 14 16 
80 12 10 16 12 14 14 14 
100 20 14 18 22 16 18 18 
140 13 18 20 22 20 20 22 
200 22 26 18 16 20 16 16 
pan 15 16 10 12 18 16 12 
Total 100 100 100 100 100 100 100 
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Blend Uniformity 
Percentage content of samples from final blend of trial batches 
were analyzed and the results are tabulated below  
Table 16. Results of Blend uniformity samples of final blend of the 
trial batches 
S.No 
F6 F7 F8 
1 96.7 97.6 98.9 
2 100.6 98.7 99.5 
3 96.7 97.4 99.9 
4 99.8 99.6 99.6 
5 99.6 98.9 99.8 
6 99.3 99.6 99.1 
7 98.1 100.2 98.1 
8 100.9 100.1 99.6 
9 97.9 100 100.8 
10 98.7 99.1 101.2 
AVG 98.8 99.1 99.65 
Min 96.7 100.2 98.1 
Max 100.9 97.4 101.2 
%RSD 1.50 1.00 0.89 
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12.4.Tablet Characterization 
Weight Variation: 
Weight variation of all the batches were evaluated and the results 
are tabulated below 
Table 17. Results for weight variation of the trial batches 
S. No 
F1 F2 F3 F4 F5 F6 F7 
1 
138.4 139.1 139.8 139,4 139.5 140.4 140.1 
2 
139.9 138.4 136.9 140.1 138.9 138.9 139.8 
3 
138.6 139.4 139.6 140.5 140.4 139.8 140.1 
4 
140.0 139.9 140.4 141.0 140.8 140.1 140.6 
5 
141.4 141.0 140.0 139.5 140.7 140.7 139.7 
6 
139.9 142.4 140.1 139.1 141.8 138.4 140.1 
7 
138.6 139.4 140.0 138.4 139.6 138.8 138.1 
8 
137.5 139.7 139.1 139.0 138.9 19.9 139.2 
9 
140.3 138.8 137.8 140.1 140.0 138.9 140.0 
10 
140.1 141.0 138.1 141.0 141.0 140.1 141.0 
Avg 
139.5 139.9 139.2 139.9 140.2 127.6 139.9 
Min 
137.5 138.4 136.9 138.4 138.9 19.9 138.1 
Max 
141.4 142.4 140.4 141.0 141.8 140.7 141.0 
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Thickness: 
Thickness of ten tablets were evaluated from each batch and 
tabulated in the table below 
Table 18. Thickness of tablets of the trial batches. 
 
 
 
 
S.No 
F1 F2 F3 F4 F5 F6 F7 
1 
3.16 3.16 3.15 3.17 3.15 3.15 3.16 
2 
3.18 3.17 3.16 3.16 3.16 3.16 3.15 
3 
3.17 3.16 3.14 3.15 3.16 3.17 3.15 
4 
3.14 3.16 3.14 3.16 3.15 3.16 3.15 
5 
3.16 3.18 3.13 3.14 3.15 3.15 3.16 
6 
3.16 3.16 3.14 3.14 3.18 3.16 3.17 
7 
3.19 3.17 3.14 3.16 3.15 3.17 3.16 
8 
3.17 3.18 3.15 3.15 3.15 3.16 3.18 
9 
3.18 3.17 3.12 3.15 3.12 3.14 3.16 
10 
3.16 3.18 3.15 3.14 3.15 3.14 3.14 
Avg 
3.17 3.17 3.14 3.15 3.15 3.16 3.16 
Min 
3.14 3.16 3.12 3.14 3.12 3.14 3.14 
Max 
3.19 3.18 3.16 3.17 3.18 3.17 3.18 
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Hardness: 
Hardness for ten tablets for the trial batches were evaluated and 
the observation was tabulated below.  
Table 19.Hardness of ten tablets and its average for the trial 
batches. 
S.No RB-
AMB-
001 
RB-
AMB-
002 
RB-
AMB-
003 
RB-
AMB-
004 
RBSU-
AMB-
005 
RBSU-
AMB-
006 
RB-
AMB-
007 
1 
10.00 10.50 10.10 9.81 10.10 11.10 9.20 
2 
10.10 10.60 10.80 9.80 10.50 10.30 10.00 
3 
10.20 10.40 10.90 10.00 10.40 10.50 9.80 
4 
10.00 10.10 10,3 11.00 10.30 10.20 9.60 
5 
9.60 10.20 9.20 11.20 10.20 9.80 10.00 
6 
10.10 9.90 10.40 10.70 10.90 10.20 9.40 
7 
9.90 9.70 9.60 10.90 11.10 10.40 10.40 
8 
10.40 9.90 9.10 11.00 10.10 10.60 10.20 
9 
9.60 10.00 9.20 9.90 9.70 10.90 10.80 
10 
10.80 10.10 9.00 10.40 9.20 10.10 10.90 
Avg 
10.07 10.14 9.81 10.47 10.25 10.41 10.03 
Min 
9.60 9.70 9.00 9.80 9.20 9.80 9.20 
Max 
10.80 10.60 10.90 11.20 11.10 11.10 10.90 
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Content Uniformity: 
Ten tablets from each batch were analysed for content uniformity 
and the results are tabulated below.  
Table 20.Results of percentage content and %RSD of tablets of trial 
batches. 
S. No 
F1 F2 F3 F4 F5 F6 F7 
1 
99.9 96.7 97.9 99.9 99.7 100.3 99.1 
2 
92.0 97.9 98.9 100.4 100.0 100.5 101.9 
3 
97.4 99.0 99.8 101.3 100.6 100.2 100.9 
4 
94.9 101.0 101.7 101.7 100.4 98.9 99.2 
5 
95.8 103.1 101.1 101.3 99.2 99.4 99.5 
6 
96.4 104.9 99,4 101.1 100.8 100.4 100.7 
7 
99.2 100.4 99.2 99.9 100.2 100.9 99.8 
8 
99.1 100.2 100.6 99.8 100.4 99.6 100.6 
9 
103.2 99.9 100.4 101.3 100.2 100.4 99.8 
10 
105.1 99.2 100.1 102.9 100.0 99.9 100.9 
AVG 
98.3 100.2 100.0 101.0 100.2 100.1 100.2 
Min 
92.0 96.7 97.9 99.8 99.2 98.9 99.1 
Max 
105.1 104.9 101.7 102.9 100.8 100.9 101.9 
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Friability: 
Initial weight, final weight and percentage weight loss of tablets 
from each batch for checking whether they pass the test for friability. 
And the results are tabulated below. 
Table 21.Friability and its parameters for all the batches. 
Parameters F1 F2 F3 F4 F5 F6 F7 
Initial 
Weight (gm) 
6.8412 6.7351 6.7638 6.9967 6.8011 6.6509 6.6789 
Final 
Weight (gm) 
6.8240 6.7102 6.7449 6.9716 6.7801 6.6499 6.6678 
Percentage 
Weight loss 
(%) 
0.41 0.37 0.28 0.36 0.31 0.01 0.17 
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Disintegration Time: 
Minimum and maximum time taken by the six tablets from each 
batch was noted and tabulated in the table below 
Table 22.Disintegration time of each batch. 
Parameters RB-
AMB-
001 
RB-
AMB-
002 
RB-
AMB-
003 
RB-
AMB-
004 
RBSU-
AMB-
005 
RBSU-
AMB-
006 
RB-
AMB-
007 
Minimum 
Time (sec) 
30 32 1.01 40 42 44 35 
Maximum 
Time (sec) 
45 47 1.25 55 53 49 45 
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12.5.Assay & Water by Kf 
Results of assay and moisture content evaluated by karlfischer 
reagent was tabulated below  
Table 23. Assay and water by kf results of the trial batches 
Parameters 
F1 F2 F3 F4 F5 F6 F7 
Assay(%) 96.70 96.80 98.7 97.9 99.2 100.4 100.2 
Water by Kf 
(%) 
5.22 5.01 4.97 4.96 4.82 4.68 4.49 
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12.6.Related substance 
The analytical method for related substance was performed and 
the highest unknown impurity and total impurity values of the respective 
batches were tabulated below. 
Table 24. Highest unknown impurity and total impurities results of 
the respective batches. 
Parameters 
F1 F2 F3 F4 F5 F6 F7 
Highest Unknown Impurity 
(%) 
0.12 0.17 0.13 0.12 0.13 0.14 0.17 
Total Impurities (%) 1.70 1.72 1.07 1.08 1.06 1.10 1.11 
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12.7.Dissolution[23] 
Percentage release of drug was analyzed during 15 minutes of 
dissolution and the results for the respective batches were tabulated 
below. 
Table 25.results of dissolution data of the trial batches. 
Dissolution Media: 0.05 M Acetate Buffer, pH 5.0. USP type II 
(Paddle) 
Spec: NLT 80%(Q) in 30 minutes 
Particulars 5 10 15 30 45 
RLD (Letairis) 65.93 72.08 85.45 91.32 98.21 
F1 47.21 54.23 59.15 65.89 72.17 
F2 51.33 57.74 61.26 67.21 75.32 
F3 56.04 61.81 69.07 72.11 79.14 
F4 62.62 68.39 72.22 76.64 81.66 
F5 69.45 75.17 81.43 88.17 94.21 
F6 74.92 79.38 84.64 90.31 99.74 
F7 79.22 85.71 91.78 98.36 99.22 
 
And the graphical representation of the batches is shown below. 
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Fig 8: Graphical representation of Percentage dissolution of the 
batches F1-F4
 
Fig 9: Graphical representation of Percentage dissolution of the 
batches F5-F7 
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12.8.Accelerated stability studies[21][22] 
30 Tablets with 6g/yard of nylon coil as dunnage is packed in 75cc 
Heavy Weight HDPE Bottle capped with 33mm Child resistant closure 
having induction seal liner is loaded along with placebo for analytical use 
in each condition. 
Particulars Assay Dissolution 
Impurity 
- D 
Any 
unknown 
impurity 
Total 
impurity 
Specification 90-110 
NMT 80% 
(Q) in 30 
minutes 
NMT 
0.5% 
NMT 
0.2% 
NMT1.0% 
F7 
(ACC - 1M) 
100.8 98 0.02 0.01 0.06 
F7 
(ACC - 2M) 
99.5 97 0.02 0.01 0.05 
F7 
(ACC - 3M) 
100.2 97 0.03 0.01 0.06 
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     13. SUMMARY AND CONCLUSION 
The present study involves formulation and evaluation of 
immediate release tablets of Ambrisentan. Endeavours with respect to 
Direct compression method used for formulating tablets was best 
suitable to achieve 100% results. 
Preformulation studies involving organoleptic bulk density, 
angle of repose, tapped density, compressibility index, hausner ratio, 
melting point range, pH and solubility were carried out as per USP 
specifications. 
Polymers such as Lactose Monohydrate, Microcrystalline 
cellulose pH 101(MCC), Croscarmellose sodium (CCS) were utilized in 
all the trails. All the physical evaluations carried in preformulation 
studies were carried out on all the three different polymers utilized. 
All the formulations exhibited values within the acceptable range. 
Tablets were evaluated for weight variations, hardness, 
friability, thickness and Dissolution studies.  
 Release studies were carried out in pH 5.0 Acetate buffer, for 45 
minutes. Evaluated samples for all the Three polymer systems. 
Results indicated that formulation F7, gave 98.36% release within 30 
minutes. Assay was carried out for formulation F7 and was found to 
be 100.2%.  
 Remaining formulations gave fluctuating release profiles. The 
formulation F7 was considered to be better among the trails 
accomplished. 
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